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ABSTRACT 
BACKGROUND: The emergence of mycobacterium tuberculosis resistance to first line 
drugs has renewed interest in second-line anti-tuberculosis drugs. Generally, Para- 
aminosalicylic acid (PAS) is less potent and frequently more toxic than the first line 
drugs. Furthermore, the pharmacokinetics of PAS in children has not been well 
characterized.  
AIMS: The aims of the present study were (1) to determine the pharmacokinetics of 
PAS in pediatric patients, (2) to describe the discrepancy between children and adult 
pharmacokinetics and the appropriate dosing regimen of PAS and (3) to investigate the 
potential of the second-line anti-tuberculosis drugs PAS, terizidone and ethionamide 
(often used as first-line drug in children) to inhibit the catalytic activities of CYP450 1A2 
and 2C9.  
PATIENTS: Twenty two patients with drug resistant tuberculosis were included in the 
study. Ten patients were children with mean age of 4.2 years (range: 1 to 12 years). 
Twelve patients were adults with mean age of 31.3 years (range: 18 to 53). 4 children 
(40%) and 4 adults (33.3%) were HIV positive and were on ART. 
METHODS: Children received 75 mg/kg twice daily on the first visit and after two weeks 
they received 150 mg/kg once. Adults received a standard 4 g twice daily. Blood 
samples were taken at different time points after the dose. In the additional study, the 
inhibitory effects of PAS, ethionamide and terizidone on phenacetin O-deethylation, a 
marker substrate of CYP1A2 and diclofenac 4’-hydroxylation, a marker substrate of 
CYP2C9, were studied using human liver microsomes. 
RESULTS: For the 75 mg/kg dose, the mean AUC was 233.3 µg•h/ml and the mean CL 
was 10.4 l/h/kg. The mean of the observed Cmax of the drug was 45.4 µg/ml and the 
mean Tmax was 4.8 hrs. For the 150 mg/kg dose, the mean AUC of PAS was 277.9 
µg•h/ml and the mean CL was 47.1 l/h/kg. The mean of the observed Cmax of the drug 
was 56.5 µg/ml and the mean Tmax was 4.8 hrs. On the first visit the mean AUC was 368 
µg•h/ml and the mean CL was 13.2 l/h/kg. The mean of the observed Cmax of PAS was 
51.3 µg/ml and the mean Tmax was 5.2 hrs.  On the second visit the mean AUC was 230 
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µg•h/ml and the mean CL was 23.9 l/h/kg. The mean of the observed Cmax of PAS was 
37.6 µg/ml and the mean Tmax was 5.2 hrs. The comparisons between pharmacokinetics 
profile of PAS and patients characteristics e.g. age, indicated no statistically significant 
differences between children (both treatment regimens) and adult patients as well as 
HIV positive and negative patients. In the in vitro study, all drugs demonstrated no 
inhibition potency towards the investigated CYP450 enzymes.  
CONCLUSIONS:The dose of 75 mg/kg twice daily in children appears to be appropriate 
to achieve serum concentration above the PAS minimum inhibitory concentration of 
approximately 1 µg/ml. PAS, ethionamide and terizidone are unlikely to affect the 
metabolism of concomitantly administered medications that are metabolized by either 
CYP450 1A2 and/or 2C9 isoenzymes.  
Stellenbosch University  http://scholar.sun.ac.za/
  
v 
 
OPSOMMING 
AGTERGROND: Die opkoming van eersteliniemiddel-weerstandige mycobacterium 
tuberculosis het opnuut belangstelling in tweedelinie-antituberkulosemiddels 
aangewakker. Oor die algemeen is para-aminosalisielsuur (PAS) minder kragtig en 
dikwels ook meer toksies. Verder is die farmakokinetika van PAS in kinders nog nie 
goed vasgestel nie.  
DOELSTELLINGS: Die doelstellings van hierdie studie was (1) om die farmakokinetika 
van PAS in pediatriese pasiënte vas te stel, (2) om die diskrepansie tussen kinder- en 
volwasse-farmakokinetika, sowel as die toepaslike doseringskedule, van PAS te beskryf 
en (3) om die potensiaal van die tweedeline-antituberkulosemiddels PAS, terisidoon en 
etioonamied (gereeld gebruik as eerste linie middels in kinders) te ondersoek wat betref 
hul vermoë om die katalitiese werking van CYP450 1A2 en 2C9 te inhibeer. 
PASIËNTE: Twee-en-twintig pasiënte met middelweerstandige tuberkulose is in hierdie 
studie ingesluit. Tien pasiënte was kinders met ‘n gemiddelde ouderdom van 4.2 jaar 
(reeks: 1 tot 12 jaar). Twaalf pasiënte was volwassenes met ‘n gemiddelde ouderdom 
van 31.3 jaar (reeks: 18 tot 53 jaar). 4 kinders (40%) en 4 volwassenes (33.3%) was 
MIV positief en was op TRM’s. 
METODES: Kinders het 75 mg/kg twee maal daaliks gedurende die eerste besoek 
ontvang en 150 mg/kg een maal ná twee weke ontvang. Volwassenes het ‘n 
standaarddosis van 4 g twee maal daagliks ontvang. Bloedmonsters is op verskillende 
tye ná die dosering geneem. In die addisionele studie is in die inhiberende effekte van 
PAS, etioonamied en terisidoon op fenasetien-O-deëtilering, ‘n merkersubstraat van 
CYP1A2 en diklofenak-4’-hidroksilasie, ‘n merkersubstraat van CYP2C9, ondersoek 
deur gebruik te maak van menslike lewermikrosome.  
RESULTATE: Vir die 75 mg/kg dosis was die gemiddelde area-onder-die-kurwe (AOK) 
233.3 µg•h/ml en die gemiddelde middelopruiming (CL) 10.4 l/h/kg. Die gemiddelde 
geobserveerde Cmaks van die middel was 45.4 µg/ml en die gemiddelde Tmaks was 4.8 h. 
Vir die 150 mg/kg dosering was die gemiddelde AOK van PAS 277.9 µg•h/ml en die 
gemiddelde CL 47.1 l/h/kg. Die gemiddelde geobserveerde Cmaks van die middel was 
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56.5 µg/ml en die gemiddelde Tmaks was 4.8 h. Gedurende die eerste besoek was die 
AOK 368 µg•h/ml en die gemiddelde CL was 13.2 l/h/kg. Die gemiddelde 
geobserveerde Cmaks van PAS was 51.3 µg/ml en die gemiddelde Tmaks was 5.2 h. 
Gedurende die tweede besoek was die gemiddelde AOK 230 µg•h/ml en die 
gemiddelde CL 23.9 l/h/kg. Die gemiddelde geobserveerde Cmaks van PAS was 37.6 
µg/ml en die gemiddelde Tmaks was 5.2 h. Die vergelyking van PAS-farmakokinetika en 
eienskappe van die pasiënte het geen statisties beduidende verskille in die gemiddelde 
AOK tussen kinders (op albei doserings) en volwassenes getoon nie. Met die in vitro-
studie het geen van die middels inhibisie-werking teenoor die CYP450-ensieme wat 
ondersoek is, getoon nie.  
GEVOLGTREKKINGS: Die gevolgtrekking kan gemaak word dat die dosering van 75 
mg/kg twee maal daagliks voldoende is om serumkonsentrasies wat bo PAS se 
minimum inhiberende konsentrasie van 1 µg/ml te bereik. Dit is onwaarskynlik dat PAS, 
etioonamied en terisidoon die metabolisme van gelyktydig-toegediende medikasies, wat 
op hul beurt deur die CYP240-isoënsieme 1A2 en/of 2C9 gemetaboliseer word, sal 
affekteer. 
 
Stellenbosch University  http://scholar.sun.ac.za/
  
vii 
 
ACKNOWLEDGMENTS 
This work was conducted at the Division of Pharmacology, University of Stellenbosch, 
during 2009-2011. During these years, I have had the privilege of being guided into the 
wonderland of research by my supervisors, Professor Bernd Rosenkranz, Head of the 
Division and Professor Patrick Bouic, Chief Scientific Officer, Synexa Life Sciences. My 
sincere thanks are due to them. I owe my sincere thanks to Professor Peter Donald, 
Professor Simon Schaaf, Senior consultants, pediatrics tuberculosis and Professor 
Andreas Diacon, Director, Task Applied Science, Brooklyn Research Centre for their 
constant guidance and their valuable contribution. 
Also, I want to thank Dr Heiner Seifart and Mr. Henry Bester for their excellent work with 
the sample preparations and analysis. I want to thank Pius Fasinu for his considerable 
help during the performance and analysis of the in vitro work. I want to thank Mr. Justin 
Harvey for his considerable help on statistical design and analysis. 
I want to thank Venessia Du Toit and Ada Pieters and their group from Task Applied 
Science, Brooklyn Research Centre. Dr Marianne Willemse from the Children ward, 
Brooklyn Chest Hospital for co-operation and practical help during the time of patient 
recruitment and sample collections, you deserve my warmest gratitude for fruitful co-
operation. Furthermore, all the participants who took part in this study are gratefully 
acknowledged. 
The whole staff and students at the Division of Pharmacology are gratefully 
acknowledged; especially Dr Ronald Gounden, Desire Fouché, Dr Erina Pretorius and 
Lejandra Hanekom deserve my deepest gratitude. Your friends make you what you are, 
if you give them the opportunity. I want to thank them all for being there whenever I 
needed them. 
My family, especially my wife Hyasinta and daughter Mary Caryn, deserve the warmest 
thanks for their support and the ultimate meaning and joy of life. 
This work has been financially supported by the Division of Pharmacology, Stellenbosch 
University and by a National Research Foundation (NRF) grant generously offered by 
Professor Peter Donald.  
Stellenbosch University  http://scholar.sun.ac.za/
  
viii 
 
ABBREVIATIONS 
ADME 
APAS 
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Acetyl-p-aminosalicylate 
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  Dimethyl sulfoxide 
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FDA   Food and Drug Administration 
FMO   Flavin dependent mono-oxygenase 
HIV   Human immunodeficiency virus 
HLMs   Human liver microsomes 
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HPLC High performance liquid chromatography 
IS Internal standard 
Ki Inhibition constant 
Km Michaelis-Menten constant 
MAO Monoamine oxidase 
MRC Medical research council 
MDR-TB   Multi drug resistant tuberculosis 
MS 
MTB 
 Mass spectrometer 
 Mycobacterium tuberculosis 
NADPH 
NAT-1 
 ß-nicotinamide adenine dinucleotide phosphate - reduced form 
  N-acetyltransferase-1 
NJ 
NSAIDS 
PAA 
  New Jersey 
  Non steroidal anti-inflammatory drugs 
  Para-aminosalicyluric acid 
PAS   Para-aminosalicylic acid 
PK   Pharmacokinetics 
QC Quality control 
SD   Standard deviation 
SE   Standard error 
SLDs   Second line drugs 
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TB Tuberculosis 
TBM  Tuberculosis meningitis 
TCH  Tygerberg Children Hospital 
Tmax   Time taken for the drug to reach maximum concentration 
USA  United States of America 
Vmax    Maximum reaction velocity 
WHO  World Health Organization 
XDR-TB    Extensively drug resistant tuberculosis 
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CHAPTER ONE 
 INTRODUCTION 
Tuberculosis (TB), an ubiquitous, highly contageous chronic granulomatous bacterial 
infection, is still a leading killer of young adults worldwide. TB has returned with a new 
face and the global scourge of multi-drug resistant TB (MDR-TB) is reaching epidemic 
proportions. It is endemic in most developing countries and resurgent in developed and 
developing countries with high rates of human immunodeficiency virus (HIV) infection. 
(Du Toit et al 2006) 
Over the past two decades, two major obstacles to global TB control have emerged. 
The first is the high prevalence of HIV among TB patients and the second is the growing 
problem of anti-TB drug resistance. Treatment for MDR-TB is longer (LoBue 2009) and 
includes the use of second-line drugs (SLDs). (Raviglione et al 2007) These drugs are 
generally less potent and frequently more toxic than isoniazid and rifampin. (Peloquin 
1993) 
Para-aminosalicylic acid (PAS), one of the SLDs was found to be effective in the 
treatment of TB in the 1940s. (Lehmann 1946) PAS was widely used in combination 
chemotherapy against Mycobacterium tuberculosis (MTB). As better tolerated 
antibiotics became available, PAS usage has diminished considerably in the past. 
However, the appearance of the widespread epidemic of MDR-TB has necessitated the 
addition of PAS to the SLDs. Hence, PAS has become one of the principle SLDs for the 
treatment of MDR-TB. (Rengarajan et al 2004) Despite the long history of PAS usage it 
has received less attention, and little information is available on its disposition and other 
factors that may influence it, especially in children. Appropriate dose adjustment of PAS 
in children using pharmacokinetic (PK) data is important in order to avoid either too high 
serum concentrations which could be toxic or too low concentrations to complete 
eradication of MTB.  
The work presented in this thesis addresses two closely related questions in order to 
determine the appropriate dose of PAS in children and the potential for drug-drug 
interactions (DDIs) with PAS and two other drugs often used in patients with MDR/XDR-
TB, terizidone and ethionamide. The main clinical part of this project was conducted in 
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order to extend our understanding of the PK of PAS in children. The PK data in children 
were compared to the data obtained in adults who served as a reference population. In 
addition, an exploratory study was performed to determine the potential of PAS, 
ethionamide and terizidone to cause DDIs via selected CYP isoenzymes. For this 
purpose, the methodology of in vitro testing of drug metabolism by the use of human 
liver microsomes (HLMs) was established. The in vitro metabolism study was conducted 
with the assumption that legacy drugs such as PAS may be substrates or inhibitors of 
the CYP enzyme system and may affect the pharmacokinetics of co-administered drugs 
metabolized by this system. Patients with TB have a high prevalence of co-morbid 
conditions that require other medications. In order to determine the potential for DDIs, 
knowledge of clearance mechanisms, enzymes responsible for drug elimination and 
modulating capabilities of enzyme activities are essential. In vitro data can guide clinical 
strategies for complex pharmacotherapy regimens. (Hyland et al 2008) Techniques for 
the study of drug metabolism in vitro are extensively utilized to provide presumptive 
answers to fundamental clinical questions regarding drug metabolism and drug 
interactions. (Greenblatt et al 2002)  
Stellenbosch University  http://scholar.sun.ac.za/
 3 
 
CHAPTER TWO 
LITERATURE REVIEW 
2.1 Burden of TB 
The estimates of the global burden of disease caused by TB in 2009 are as follows: 9.4 
million incident cases (range, 8.9 million-9.9 million). (WHO 2010) HIV infection has 
been described as a driving force of the TB epidemic in the most affected populations. A 
study conducted in peri-urban communities in South Africa has shown that TB 
notification rates have increased 2.5-fold, reaching a rate of 1468 cases per 100,000 
persons in 2004. The estimated population prevalence of HIV infection increased from 
6% to 22% during the same period. After stabilization of prevalence of the HIV infection, 
the TB notification rate continued to increase steeply, indicating ongoing amplification of 
the TB epidemic. In 2004, at least 50% of children aged 0-9 years who developed TB 
were HIV infected. Annual TB notification rates among adolescents increased from 0 
cases in 1996-1997 to 436 cases per 100,000 persons in 2003-2004, and these 
increases were predominantly among females. However, 20-39 year-old persons were 
affected most, with TB notification rates increasing from 706 to 2600 cases per 100,000 
persons among subjects in their 30s. In contrast, TB rates among persons aged >50 
years did not change. In this study 98 (59%) of 166 persons who provided TB 
notifications were HIV positive. On the basis of these data, the TB notification rate 
among HIV-infected individuals was calculated to be 4381 cases per 100,000 persons 
(95% CI, 3570-5313 cases per 100,000 persons. (Lawn et al 2006) 
Children are mainly infected by adult pulmonary TB source cases, and childhood TB 
therefore reflects the intensity of ongoing transmission of MTB within a community. 
(Schaaf et al 2005) Since most children acquire the organisms from adults in their 
surroundings, the epidemiology of childhood TB follows that in adults. An estimated 
10% of the 2.9 million new cases of TB in sub-Saharan Africa during 2007 occurred in 
children: 38% of all incident TB cases in sub-Saharan Africa (regardless of age group) 
were HIV-infected in 2007. (WHO 2009) TB case load studies in children suggest an 
exponential rise in the proportion of the TB case load in children as the prevalence of 
TB rises, nearly 40 per cent of the case load in certain high incidence communities. 
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(Donald 2002) In Cape Town, South Africa, children suffer considerable morbidity: 
207/439 (47.1%) had disease manifestations other than uncomplicated lymph node 
disease, while 26/439 (5.9%) were diagnosed with disseminated (miliary) disease 
and/or TB meningitis (TBM). (Marais et al 2004) 
2.2 Drug-resistant TB 
The treatment and control of TB is more complex when the organism is resistant to the 
action of anti-TB drugs. MDR-TB is associated with mortality as high as 43-93% in 
adults. Despite limited information in children, resistance patterns in children have 
generally been found to be similar to those of adults from the same areas and similar 
backgrounds. (Nelson et al 2004) Traditionally, patients with drug-resistant TB are 
classified as having acquired or primary drug resistance on the basis of a history of 
previous treatment. In a survey in 35 countries, the median prevalence of primary 
resistance to any anti-TB drug was 9.9% (range 2-41) and that of acquired resistance 
was 36%. (Van Rie et al 2000) In a study conducted at Tygerberg Children Hospital 
(TCH), Cape Town, among 313 children (range 2 weeks-12.9 years) in whom drug 
susceptibility test (DST) results were available, 40 (12.8%) and 17 (5.4%) were infected 
with strains resistant to isoniazid and rifampicin, respectively. All who had rifampicin-
resistant strains had co-existent resistance to isoniazid (MDR-TB). Only 1/40 (2.5%) 
children with resistance to isoniazid and/or rifampicin were also resistant to ethambutol 
(Schaaf et al 2007). In a study conducted in Johannesburg, South Africa, the MDR-TB 
prevalence rate of 8.5% was higher than in previous studies (2.3-6.7%). These results 
suggest a high prevalence of MDR-TB. (Fairlie et al 2011)  
XDR-TB has now been reported from 45 countries, though this almost certainly 
underestimates its true extent as many countries lack laboratory facilities to detect 
resistance to SLDs. The outbreak in South Africa was particularly alarming because 
most patients with XDR-TB had no history of TB treatment, implying person to person 
transmission of XDR-TB, and because of evidence of transmission in healthcare 
settings. (Grant et al 2008)  
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2.3 Pharmacokinetics 
PK is the discipline that applies mathematical models to describe and predict the time 
course of drug concentrations in body fluids. (Greenblatt et al 2002) PK measures, such 
as area under the curve (AUC), maximum concentration (Cmax) and parameters 
calculated from those measures, such as clearance, half life, and volume of distribution, 
reflect the absorption, distribution and elimination of a drug from the body. A drug can 
be eliminated by metabolism to one or more active or inactive metabolites and by 
excretion of the unchanged drug. The overall set of processes is often referred to as 
ADME (Absorption, Distribution, Metabolism and Excretion), which ultimately controls 
systemic exposure to a drug and its metabolites after drug administration. Systemic 
exposure reflected in plasma drug and/or metabolite concentrations is generally used to 
relate dose to both beneficial and adverse effects. All drugs show inter- and intra-
individual variance in PK measures and/or parameters. Variance can sometimes be 
substantial. In the pediatric population, growth and developmental changes in factors 
influencing ADME also lead to changes in PK measures and/or parameters. (Gilman 
1992, Butler et al 1994) 
PK studies have led to the appreciation of the large degree of variability in PK 
parameter estimates that exist across individuals; many studies have quantified the 
effect of factors such as age, gender, disease states and concomitant drug therapy on 
the PK of drugs, with the purpose of accounting for individual variability. (Atkinson Jr et 
al 2007) 
PK of xenobiotics can differ widely between children and adults due to physiological 
differences and the immaturity of enzyme systems and clearance mechanisms. This 
makes extrapolation of adult dosimetry estimates to children uncertain, especially at 
early postnatal ages. Once exposure has occurred, the PK handling of xenobiotics is 
likely to differ from that in adults with respect to their metabolism, clearance, protein 
binding and volume of distribution. (Ginsberg et al 2001) Key factors explaining 
differences in drug distribution between the pediatric population and adults are organ 
size, membrane stability, plasma protein concentration and characteristics, endogenous 
substances in plasma, total body and extracellular water, fat content, regional blood flow 
and transporters such as P-gp, which is present not only in the gut, but also in liver, 
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kidney, brain and other tissues. (Benedetti et al 2005) The changes in body size and 
maturation during development of the children affect PK concentration-time profiles. 
(Anderson et al 2006) 
Developmental changes are responsible for differences in drug disposition seen 
throughout childhood; therefore the weight-adjusted drug dose may not be the same for 
different age groups. During a period of latent or rapid growth, some drugs that may 
cause severe or protracted toxicity can alter the final mature expression of a system. 
These concepts need to be appreciated for appropriate use of drugs in children. Age-
related differences in PK, in addition to those of body size, can be used to guide 
calculations. Altered absorption, distribution, and elimination are most marked in the 
newborn, but for many drugs, disposition processes may equal or exceed the adult 
capacity by late infancy and/or childhood. (Pradhan et al 1986) Areas of importance in 
pediatric PK are as follows:  
Absorption: Developmental changes in the pediatric population that can affect 
absorption include effects on gastric acidity, rates of gastric and intestinal emptying, 
surface area of the absorption site, gastrointestinal enzyme systems for drugs that are 
actively transported across the gastrointestinal mucosa, gastrointestinal permeability, 
and biliary function. Similarly, developmental changes in skin, muscle and fat including 
changes in water content and degree of vascularization, can affect absorption patterns 
of drugs delivered via intramuscular, subcutaneous or percutaneous routes. (Yaffe 
1992) 
Distribution: Distribution of a drug may be affected by changes in body composition, 
such as changes in total body water and adipose tissue that are not necessarily 
proportional to changes in total body weight. Plasma protein binding and tissue binding 
changes arising from changes in body composition with growth and development may 
also influence distribution. (Gilman 1990) 
Metabolism: Important differences have been found in the pediatric population 
compared to adults both for phase I and II enzymes, reductive and hydrolytic enzymes. 
Generally, the major enzyme differences observed in comparison with the adult age are 
in newborn infants, although for some enzymes e.g. glucuronosyl-transferases 
important differences still exist between infants and toddlers and adults. (Benedetti et al 
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2005) A study that investigated the role of the NAT2 genotype and enzyme maturation 
on isoniazid PK showed that improved phenotypic expression of NAT2 with age extends 
beyond the neonatal period. (Zhu et al 2011) 
Excretion: Drug elimination clearance may increase with weight, height, age, body 
surface area and creatinine clearance. (Anderson and Holford 2008) Because these 
processes mature at different rates in the pediatric population, age can affect systemic 
exposure for drugs where renal excretion is a dominant pathway of elimination. 
Consideration should also be given to the maturation of other excretory pathways, 
including biliary and pulmonary routes of excretion. (Brown 1989)  
 
2.4 Drug biotransformation (Metabolism) 
Drug biotransformation is one of the most important factors that can affect the overall 
therapeutic and toxic profile of a drug. It can lead to detoxification and excretion of the 
drug, but also to bioactivation. (Brandon et al 2003)  
A typical chemical metabolism pathway involves the oxidation of the parent substance 
(phase I oxidation), followed by conjugation of the oxidised moiety with highly polar 
molecules, such as glucose, sulphate, methionine, cysteine, glutathione or glucuronic 
acid (phase II conjugation) (Xu et al 2005).  
The key enzymes for phase I oxidation are the isoforms of the CYP family of enzymes. 
Regulated by nuclear receptors (Honkakoshi and Negishi 2000), the superfamily of 
CYPs are heme containing enzymes with very wide substrate specificities by virtue of 
their existence in a large number of isoforms or isozymes. While the liver is the main 
site of xenobiotic metabolism, it is important to note that phase I and II metabolism also 
occurs in most tissues and the gut microflora. (Nishimura et al 2003) Usually, these 
conversions result in a decrease in toxicity and/or an increased excretion of the 
chemical. However, metabolic activation is also possible, which can also be inhibited or 
induced by pharmaceutical, environmental and/or dietary chemicals. (Nakajima et al 
2001)  
Several factors can alter drug metabolism, including the presence or absence of 
disease and/or concomitant medications. While most of these factors are usually 
relatively stable over time, concomitant medications can alter metabolism abruptly and 
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are of particular concern. The influence of concomitant medications on metabolism 
becomes more complicated when a drug is metabolized to one or more active 
metabolites. In this case, the safety and efficacy of the drug are determined not only by 
exposure to the parent drug but by exposure to the active metabolites. (Huang et al 
2007) The activity of many CYP isoforms and a single glucuronosyltransferase (UGT) 
isoform is markedly diminished during the first two months of life. In addition, the 
acquisition of adult activity over time is enzyme and isoform-specific. (Kearns at al 
2003) 
Although several enzyme systems participate in phase I metabolism of xenobiotics, 
perhaps the most notable pathway in this scheme is the monooxygenation function 
catalyzed by the cytochrome P450s (CYPs; P450s) as discussed in detail below. The 
CYPs detoxify and/or bioactivate a vast number of xenobiotic chemicals and conduct 
functionalization reactions that include N- and O-dealkylation, aliphatic and aromatic 
hydroxylation, N- and S-oxidation, and deamination. Examples of toxicants metabolized 
by this system include nicotine and acetaminophen, as well as the procarcinogenic 
substances, benzene and polyaromatic hydrocarbons. (Omiecinski et al 2011)  
2.5 In vitro models of drug metabolism 
In vitro systems are well established as valuable tools for studying various aspects of 
drug metabolism; in particular, kinetic data obtained from in vitro systems can be scaled 
and used in the prediction of in vivo clearance. (Parker and Houston 2008) Since the 
liver is the primary site of systemic metabolism, preparations from hepatic tissue are 
mostly used. In vitro hepatic metabolism can be measured in many different 
preparations that include the smallest and the least complex microsomes or cytosol, up 
to isolated hepatocytes, slices and perfused tissue. Subcellular fractions (i.e., cytosol, 
microsomes) have been used for decades in studies of xenobiotic metabolism. These 
preparations are cost-effective to prepare or to procure, are relatively stable over time, 
and offer a good means of isolating a group of enzymes. However, the nature of these 
preparations containing groups of enzymes often co-located to the same cellular 
compartment-produces a disadvantage compared to purified or recombinant systems 
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when attempting to study the metabolic contributions of a single enzyme. (Lipscomb et 
al 2008)  
Microsomal protein is usually separated from the other constituents of the cell by 
differential ultracentrifugation (Guengerich 1994) and consists primarily of the enzymes 
associated with the endoplasmic reticulum. Microsomes contain CYPs, flavin-containing 
monooxygenases (FMO) and glutathione S-transferases. Metabolic activity is often 
initiated by the addition of substrate or cofactor, and the time of incubation is easily 
controlled. Because cofactors are exogenously added, they can be infinitely controlled 
and are typically added as native cofactor or in a cofactor regenerating system. 
(Lipscomb et al 2008) 
 
2.6 Liver microsomes 
Liver microsomes consist of vesicles of the hepatocyte endoplasmic reticulum and are 
prepared by differential centrifugation and thus contain almost only CYP and UGT 
enzymes. Liver preparations, other than from fresh human liver, can also be used (e.g., 
liver slices, liver cell lines, and primary hepatocytes) for preparation of microsomes. The 
CYP and UGT enzyme activity can be measured by various model substrates. In 
commercially available human liver microsomes (HLMs), the CYP activity is already 
characterized by the supplier. NADPH regenerating system or NADPH is required to 
supply the energy demand of the CYPs and UDPGA and alamethicin for UGT activity. 
The activity of HLMs can vary substantially between individuals. This problem, however, 
can be successfully solved by the application of pooled microsomes, which results in a 
representative enzyme activity. These pools can be purchased from different 
companies. Individual HLMs can also be used to screen for the inter-individual 
variability in the biotransformation of a drug. It is also possible to identify the critical CYP 
involved in the biotransformation of the drug using individual HLMs by correlating the 
enzyme activity of a particular CYP, using a bank of human donors, to the metabolism 
of the drug. (Brandon et al 2003) Therefore they are widely used as an in vitro model 
system in order to investigate the metabolic fate of xenobiotics. The most prominent 
group of drug metabolizing enzymes is the super family of CYPs. These haem-
containing enzymes play a key role in the metabolism (mainly oxidation) of a variety of 
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chemically diverse compounds including food compounds, pharmaceutical agents, 
carcinogens, and environmental pollutants. (Pelkonen and Turpeinen 2007) 
The preparation procedure includes the homogenization of a liver, followed by 
centrifugation at 9000 or 10000 g to remove nuclei, plasma membranes, and large 
organelles such as mitochondria. The resulting supernatant S9 is defined as the 
"supernatant fraction obtained from an organ (usually liver) homogenate by centrifuging 
at 9000 g for 20 minutes in a suitable medium; this fraction contains cytosol and 
microsomes." The microsome component of the S9 fraction contains cytochrome P450 
isoforms (phase I metabolism) and other enzyme activities and S10 is the cytosolic 
fraction containing ribosomes and endoplasmic reticulum. (Duffus et al 2007)  
Another centrifugation at 100000 g will pellet the endoplasmic reticulum which is the site 
of the CYP450s. This pellet is termed “microsomes”. HLMs are used extensively for 
drug metabolism and DDIs. (Li 2004) The enzymatic activities are stable during the 
prolonged storage of the microsomes. In order to reflect the standard proportion of the 
enzymes in human or animal livers, liver microsomes are usually pooled. The major 
disadvantage of the model is the limited incubation time (the enzyme activities decrease 
after 2 hours of incubation). (Baranczewski et al 2006) 
 
 2.7 Cytochrome P450 Inhibition  
Drug inhibition is usually regarded as potentially dangerous, or at least undesirable. A 
drug that inhibits a specific CYP450 enzyme can decrease the metabolic clearance of a 
co-administered drug that is a substrate of the inhibited enzyme. A consequence of 
decreased metabolic clearance is elevated blood concentrations of the co-administered 
drug, which may cause adverse effects or enhanced therapeutic effects. In addition, the 
inhibited metabolic pathway can lead to the decreased conversion of a pro-drug to its 
active form, resulting in reduced efficacy e.g. tamoxifen, codeine and clopidogrel. 
(Mannheimer and Eliasson 2010) Unwanted effects are most obvious and expected 
when they involve drugs with narrow therapeutic range, e.g. warfarin. (Lowery et al 
2005) To determine whether a compound inhibits CYP activity, changes in the 
metabolism of a CYP-specific substrate by HLMs or hepatocytes at various 
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concentrations of the compound are monitored. Potency and rank order of the inhibition 
of CYP enzymes can be assessed by the determination of the IC50 and Ki.  
The inhibition constant, Ki, denotes the equilibrium constant of the dissociation of the 
inhibitor-bound enzyme complex, while the IC50 value quantifies the concentration of 
inhibitor necessary to halve the reaction rate of an enzyme-catalyzed reaction observed 
under specified assay conditions. (Burligham and Widlanski 2003) 
Ki values are determined with HLMs and CYP isoenzyme selective substrates over a 
range of concentrations for both probe substrates and the compound. Unlike IC50, Ki 
values are intrinsic values, which represent the extent to which a compound will affect a 
given CYP isoenzyme. Since the Ki values describe specific equilibrium-based 
interactions between the investigational drug and the tested CYP isoenzyme, these can 
be used to correlate in vitro inhibitory concentrations to predict in vivo plasma 
concentrations. (Bjornsson et al 2003) 
 
 
Figure 1: Proportion of drugs metabolized by different families of CYP450 enzymes 
(Wrighton and Steven 1992). 
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2.8 CYP450 enzymes 
Drug metabolism in general consists of an oxygenation step, adding an oxygen moiety, 
usually a hydroxyl group, to the organic molecule. This is generally referred to as 
“phase I oxidation.” The most important phase I drug metabolizing enzymes belong to 
the cytochrome P450 (CYP) family, with the key human isoforms being CYP1A2, 
CYP2A6, CYP2B1, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4, each with 
isoforms-specific substrates. CYP3A4 is believed to be the most abundant and 
important, being responsible for the metabolism of near 50% of the existing drugs. The 
CYP isoenzymes are responsible for the elimination of numerous xenobiotics. Inhibition 
or induction of CYP enzymes by other compounds may significantly alter plasma 
concentrations of drugs that are substrates for these enzymes. (Faber et al 2005) 
The CYP superfamily of drug metabolizing enzymes is now established as being of 
primary importance for the metabolism and clearance of most drugs. For the CYP 
isoforms most relevant to human drug metabolism, each has its own distinct pattern of 
relative abundance, anatomic location, mechanism of regulation, substrate specificity, 
and susceptibility to inhibition and induction by other drugs or foreign chemicals. CYP 
comprises a superfamily of haemoproteins which functions as the terminal oxidase of 
the mixed function oxidase system. At least 481 CYP genes and 22 pseudogenes are 
known to exist across all species. Pseudogenes are dysfunctional relatives of genes 
that have lost their protein-coding ability or are otherwise no longer expressed in the 
cell. (Vanin 1985) These CYP genes are classified into families (designated by an 
arabic numeral) and subfamilies (designated by a letter) according to the amino acid 
identity of the encoded proteins. Of the thirty-five known human CYP genes, currently 
classified in families 1,2,3,4,5,7,8,11,17,19,21,24,27 and 51, only the eighteen forms 
comprising families 1 to 3 appear to substantially contribute to the metabolism of drugs 
and non-drug xenobiotics. The remainders are of importance in the metabolism and/or 
biosynthesis of endogenous compounds such as bile acids, biogenic amines, 
eicosanoids, fatty acids, phytoalexins, retinoids and steroids. (Miners and Birkett 1998)  
 
In this thesis, only two CYP450 isoenzymes (CYP1A2 and CYP2C9) have been 
described, this was necessitated by the fact that this was only an initial exploratory 
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study which gave way to the ongoing more detailed in vitro study at the Division of 
Pharmacology. The selection of these two isoforms was based on practical 
considerations, such as the availability of standards and HPLC/MS/MS methods. 
 
2.8.1 CYP1A subfamily 
CYP1A subfamily enzymes are well known to play an important role in the metabolism 
of various carcinogens and drugs. For example, CYP1A1 and CYP1A2 catalyze the 
metabolic activations of the carcinogenic aryl hydrocarbons and aromatic amines, 
respectively. Furthermore, the activities of CYP1A1 and CYP1A2 in target tissues are 
one of the host factors that determine the susceptibility of experimental animals toward 
carcinogenic aryl hydrocarbons and aromatic amines respectively. (Kojima et al 2010) 
HLMs contain relatively high constitutive levels of CYP1A2 (10-15% of the total P450 
content of human liver).  CYP1A2 metabolizes many clinically important drugs such as 
amitriptyline, imipramine, theophylline, clozapine, tacrine, and zileuton. Most of the 
investigators use phenacetin O-deethylation to form acetaminophen to represent 
CYP1A2 activity. However, industry investigators also use several substrates other than 
phenacetin to evaluate CYP1A2 activity. The frequent use of this substrate in vitro is 
due to the availability of a fast and simple high-performance liquid chromatography-
ultraviolet detection assay with high sensitivity for the reaction. In HLMs, the O-
deethylation of phenacetin displays biphasic kinetics. Studies with cDNA-expressed 
CYP1A2 chemical inhibitors and monoclonal antibodies show that the high-affinity 
component of phenacetin O-deethylation is CYP1A2. The Km value of this pathway is 
reported at 10 to 50 µM, at least 10-fold lower than that of the low-affinity component. At 
a substrate concentration of 100 µM, the contribution of CYP1A2 is estimated to be 
86%, but the contribution is reduced to 50% at a substrate concentration of 500 µM.  
At concentrations ≥500 µM, several enzymes, especially CYP2C9, contribute 
significantly to the O-deethylation of phenacetin in HLMs. Studies with organic solvents 
have indicated that at solvent concentrations ≤1% (v/v), phenacetin O-deethylation is 
not significantly affected by dimethyl sulfoxide (DMSO) and methanol.  
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In summary, at substrate concentrations that reflect low Km enzyme activity (i.e., at 
concentration lower than 100 µM), phenacetin O-deethylation is the preferred probe 
reaction for detecting CYP1A2-based DDIs potential in vitro. (Yuan et al 2002) 
 
2.8.2 CYP2C subfamily 
The CYP2C subfamily is the second most abundant CYP protein in the human liver, 
representing about 20% of the total CYP. (Shimada et al 1994) CYP2C9 is one of four 
known members of the human CYP2C subfamily, although genomic analysis suggests 
the possible existence of three additional CYP2C enzymes. Other known members of 
the human CYP2C subfamily include CYP2C8, CYP2C18 and CYP2C19. While 
CYP2C10 was originally also considered a discrete isoform, this enzyme is now thought 
to be a variant of CYP2C9. (Miners and Birkett 1998)  
CYP2C9 is the principal CYP2C in human liver. It metabolizes many clinically important 
drugs including the diabetic agent tolbutamide, the anticonvulsant phenytoin, the S-
enantiomer of the anticoagulant warfarin, ∆1-tetrahydrocannabinol and numerous anti-
inflammatory drugs such as ibuprofen, diclofenac, piroxicam, tenoxicam, mefenamic 
acid, the antihypertensive losartan and several new drugs including the antidiabetic 
drug glipizide and the diuretic torasemide. (Goldstein 2002)  
Diclofenac, tolbutamide, phenytoin, and celecoxib are structurally diverse CYP2C9 
substrates. The first three compounds have been well established as the probes for 
CYP2C9 activity in human liver. (Tang et al 2000) Fluconazole, miconazole and 
sulfamethoxazole are potent inhibitors of CYP2C9. Co-administration of phenytoin, 
warfarin, sulfamethoxazole and losartan with fluconazole results in clinically significant 
drug interactions. (Venkatakrishnan et al 2000) 
Although CYP2C9 activities are predominant in the liver, CYP2C8 and CYP2C9 
activities overlap in that both enzymes can metabolize arachidonic acid, several 
NSAIDs, retinoic acid and others. CYP2C8 separately metabolizes various endogenous 
compounds including arachidonic acid, retinoic acid, and therapeutic drugs such as the 
widely used chemotherapeutic agent paclitaxel. (Speed et al 2009) 
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Table 1: Summary of xenobiotic-metabolizing human hepatic CYP450. 
 
CYP Relative 
amount in 
the liver 
(%) 
Substrates (reaction) 
 
Selective 
inhibitors 
Other 
characteristics 
1A2 ~10 Ethoxyresorufin (O-
deethylation) 
Phenacetin (O-deethylation) 
Furafylline  Inducible 
2A6 ~10 Coumarin (7-hydroxylation)   Polymorphic 
2B6 ~1 S-Mephenytoin (N-
demethylation)  
Orphenadrine  
2C8 <1 Paclitaxel (6α-hydroxylation) Quercetin  
2C9 ~20 Tolbutamide 
(methylhydroxylation) 
Diclofenac (hydroxylation) 
S-Warfarin (7-hydroxylation) 
Sulfaphenazole Polymorphic 
2C19 ~5 S-mephenytoin (4’-
hydroxylation) 
Omeprazole (oxidation) 
 
 Polymorphic 
2D6 ~5 Dextromethorphan (O-
demethylation) 
Debrisoquine (4-
hydroxylation) 
Bufuralol (1’-hydroxylation) 
 
Quinidine Polymorphic 
2E1 ~10 Chlorzoxazone (6-
hydroxylation) 
Aniline (4-hydroxylation) 
 
Pyridine Inducible 
3A4 ~30 Midazolam (1’- and 4-
hydroxylation) 
Testosterone (6β-
hydroxylation) 
Nifedipine (dehydrogenation) 
Azole 
antimycotics 
Inducible 
Data adapted from (Pelkonen and Breimer 1994) and (Pelkonen et al 1998; 2000). 
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2.9 Drug-drug interactions 
Concomitant administration of several drugs is common and, indeed is often the 
situation in hospitalized patients. Whenever two or more drugs are administered over 
similar or overlapping time periods, the possibility for drug interactions exists. (Jiunn et 
al 1997)  
DDIs were already recognized as a potential problem in the late 1960s. Over the last 4 
decades, the problem has increased in magnitude with the introduction of several new 
classes of drugs. Prospective evaluations of DDIs indicate that the incidence of clinically 
significant DDIs probably lies between 1 and 10 in 1000 patients. Among these DDIs, a 
significant fraction is metabolic in nature, and is associated with inhibition of the 
enzymes responsible for drug clearance. (Yao et al 2001)  
DDIs are of great interest to scientists involved in drug research, regulatory authorities 
who are responsible for public safety, physicians, and their patients. Since 
“polypharmacy”, or the practice of simultaneous prescription of more than one drug to 
treat one or more conditions in a single patient, has become a more common practice, 
drug interactions have been cited as one of the major reasons for hospitalization and 
even death. (Walsky et al 2004) A patient may be co-administered multiple drugs to 
allow effective treatment of a disease (e.g., TB, HIV infection) or for the treatment of 
multiple diseases or disease symptoms. It is now known that DDIs may have serious, 
sometimes fatal consequences. (Li 2007)  
Interactions by mutual competitive inhibition between drugs is almost inevitable, 
because metabolism represents a major route of drug elimination and because many 
drugs can compete for the same enzyme system. The risk of clinical consequences 
from DDIs is higher with some drugs than with others. (Jiunn et al 1997)  
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Figure 2: The effects of drug A on drug B through (A) direct induction/inhibition of 
enzymes; (B) indirect induction/inhibition of transcription factors that regulate the drug-
metabolizing enzymes. (Tari et al 2010) 
 
Many metabolic routes of elimination, including most of those occurring via the CYP 
family of enzymes, can be inhibited, activated, or induced by concomitant drug 
treatment. Observed changes arising from metabolic interactions can be substantial in 
order of magnitude or more decrease or increase in the blood concentration of a drug or 
metabolite and can include formation of toxic metabolite or increased exposure of a 
Stellenbosch University  http://scholar.sun.ac.za/
 18 
 
parent compound. Depending on the extent and consequence of the interaction, the fact 
that drug metabolism can be significantly inhibited by other drugs and that the drug itself 
can inhibit the metabolism of other drugs can require important changes in either its 
dose or the dose of drugs with which it interacts, that is, on its labeled condition of use. 
Even drugs that are not substantially metabolized can have important effects on the 
metabolism of concomitant drugs. For this reason, metabolic DDIs should be explored, 
even for an investigational compound that is not eliminated significantly by metabolism. 
(Huang et al 2007) 
Although modulation of other proteins such as p-glycoprotein and UDP-
glucuronosyltranferases by co-administered drugs causes adverse side effects, 
inhibition of CYPs are currently recognized as the major mechanism for DDIs observed. 
As the most important drug metabolism enzymes in humans, CYP are responsible for 
metabolizing more than 95% of marketed drugs. Therefore, in vitro assessment of 
potential drug interactions has largely been focused on inhibition of CYPs. (Yan and 
Caldwell 2004) Several drugs in common use cause large increases in exposure to 
other drugs. Examples include ketoconazole, itraconazole, erythromycin, 
clarythromycin, diltiazem and nefazodone (CYP3A4); enoxacin (CYP1A2); and 
sulfaphenazole (CYP2C9); with some drugs possessing the potential to inhibit more 
than one P450 enzyme; fluconazole (CYP2C9 and CYP2C19) and fluvoxamine 
(CYP1A2 and CYP2C19). (Walsky et al 2004)  
 
2.10 The rate of inhibition 
The rate of inhibition depends on the affinity of the substrate for the enzyme being 
inhibited, the concentration of substrate required for inhibition, and the half-life of the 
inhibitor drug. The onset and offset of enzyme inhibition are dependent on the half-life 
and time to steady-state of the inhibitor drug. The time to maximum drug interaction 
(onset and termination) is also dependent on the time required for the inhibited drug to 
reach a new steady state. (Leucuta and Vlase 2006) 
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2.11 Enzyme induction 
Enzyme induction is not as common as inhibition based drug interactions, but equally 
profound and clinically important. Enzyme induction occurs when hepatic blood flow is 
increased, or the synthesis of more CYP450 enzymes is stimulated. Like inhibitors, 
inducers tend to be lipophilic, and the time course of the interaction is dependent on the 
half-life of the inducer. The time course of induction is also dependent on the time 
required for enzyme degradation and new enzyme production. The half-life of CYP450 
enzyme turnover ranges from 1 to 6 days. Enzyme induction is also influenced by age 
and liver disease. The ability to induce drug metabolism may decrease with age, and 
patients with cirrhosis or hepatitis may be less susceptible to enzyme induction. 
(Leucuta and Vlase 2006) 
Table 2 lists some of the substrates metabolized by CYP isoenzymes and the agents 
which inhibit or induce these enzymes. This does not imply that any combination of 
inhibitor and substrate for a particular isoenzyme will result in an interaction of clinical 
significance.  
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Table 2: Examples of drugs with clinically important effects on CYP isoenzymes 
Drug Inhibition of: Induction of: 
 
Azole antifungals 
  Ketoconazole  
  Itraconazole  
  Fluconazole  
  Terbinafine  
 
 
CYP3A 
CYP3A 
CYP3A, 2C9  
CYP2D6 
 
 
Antidepressants 
  Fluoxetine  
  Paroxetine  
  Fluvoxamine  
  Nefazodone  
  St. Johns wort 
 
CYP2D6 
CYP2D6 
CYP1A2, 2C19, 3A 
CYP3A 
 
 
 
 
 
CYP3A 
 
Antipsychotics 
  Perphenazine  
 
CYP2D6 
 
 
Anticonvulsants 
  Carbamazepine  
 
 
 
CYP3A 
 
Antithrombotics 
  Ticlopidine  
 
CYP2D6, 2C19 
 
 
Antiinfectives 
  Erythromycin  
  Clarithromycin  
  Ciprofloxacin  
  Rifampin  
 
CYP3A 
CYP3A 
CYP1A2 
 
 
 
 
CYP3A 
 
Viral protease inhibitors 
  Ritonavir  
 
CYP3A  
 
CYP2C9, 2C19 
 
Nonnucleoside reverse 
transcriptase inhibitors 
  Delavirdine  
Nevirapine  
Efavirenz 
 
 
 
CYP3A 
 
 
 
CYP3A4, 2B6 
CYP2C9, 2C19, 3A4 
Cardiovascular agents 
  Quinidine  
  Diltiazem  
  Verapamil  
 
CYP2D6 
CYP3A 
CYP3A 
 
 
Antiulcer agents 
  Omeprazole  
 
CYP2C19 
 
Adapted from (Greenblatt et al 2002) 
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2.12 Second-line anti-TB drugs 
The backbone of regimens for the treatment of MDR-TB consists of an injectable drug 
(aminoglycoside or polypeptide) and a fluoroquinolone, supported by at least two 
additional SLDs in order to ensure that the regimen includes at least four drugs 
confirmed or expected to be effective. Aminoglycosides, polypeptides and 
fluoroquinolones are bactericidal, while thionamides, cycloserine/terizidone and PAS 
are bacteriostatic. Once the injectable drugs (i.e. aminoglycosides) and the 
fluoroquinolones are compromised by resistance, available treatment regimens become 
much weaker and the possibility for patient cure decreases significantly. Significantly 
more clinical data are needed to answer key questions relating to treatment outcomes in 
the presence of different combinations and permutations of drug resistance. (WHO 
2008) 
 
2.12.1 Para-aminosalicylic acid (PAS) 
PAS was the second antibiotic found to be effective in the treatment of TB in the 1940s. 
(Lehmann 1946) It is at least as effective as other SLDs and probably more effective. 
(Peloquin et al 1994) PAS was widely used in combination chemotherapy against MTB. 
However, PAS caused gastrointestinal toxicity leading to poor patient compliance. As 
more easily tolerated antibiotics became available, PAS usage diminished considerably. 
The appearance of widespread epidemic of MDR-TB has necessitated the addition of 
PAS to the first line agents. The advancement of a new formulation of the drug with 
fewer gastrointestinal side effects has supported the use of this drug. Thus, PAS has 
become one of the principle SLDs for the treatment of MDR-TB. (Rengarajan et al 2004)  
An improved (granule) formulation of PAS has been used to treat patients with MDR- 
TB or patients who are intolerant of first-line anti-TB medications. This formulation, 
dosed as 4 grams (one packet of granules) in adults or 75 mg/kg body weight in 
children every 12 hours has several notable advantages over previous preparations. 
(Berning et al 1998) 
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Mechanism of action 
The mechanism of action of PAS has yet to be elucidated, and it is believed that the 
mechanism is related to interference with bacterial folic acid synthesis and inhibition of 
iron uptake.   The binding of PAS to pteridine synthetase is the first step in folic acid 
synthesis. PAS binds pteridine synthetase with greater affinity than para-aminobenzoic 
acid (PABA), effectively inhibiting the synthesis of folic acid. As bacteria are unable to 
use external sources of folic acid, cell growth and multiplication slows. PAS may inhibit 
the synthesis of the cell wall component, mycobactin, thus reducing iron uptake by 
MTB. (Arbex et al 2010) 
Pharmacokinetics 
The ingestion of 4 g of PAS granules leads to a maximum serum concentration of 20-60 
µg/ml after 4-6 hrs. The serum levels of PAS peak within 90-120 min after the ingestion. 
The half life of PAS is 1 hr, and the plasma concentrations of the drug after 4-5 hrs are 
minimal, which justifies the need for doses of 10-12 g in order to maintain the 
bacteriostatic activity. PAS is metabolized in the intestines and liver, via acetylation, into 
N-acetyl-para-aminosalicylic acid. More than 80% of the drug is excreted by the kidney 
through glomerular filtration and tubular secretion. (Peloquin 2002) 
Metabolism 
There are two main products of the metabolism of PAS; acetylation by N-
acetyltransferase-1 (NAT1) to form N-acetyl-p-aminosalicylate (APAS) and conjugation 
with glycine to form p-aminosalicyluric acid (PAA) accounting for approximately 70% 
and 25% of the absorbed dosage. (Wan et al 1974) A considerable proportion of 
metabolism occurs in the gut and liver and this first-pass effect can exercise a 
considerable effect on resulting blood concentrations.  This first-pass effect also 
appears to be rate-limited and consequently higher PAS dosages lead to relatively 
higher blood concentrations of PAS and PAA, but this also has the consequence of 
more rapid excretion. (Lehman 1969) APAS appears to have little tuberculostatic effect, 
but PAA is reported to have approximately 75% of the inhibitory effect of PAS. (Lehman 
1969) 
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Adverse effects 
Gastrointestinal effects (anorexia, diarrhea, nausea, and vomiting) and hypothyroidism, 
the latter occurring especially when PAS is administered concomitantly with 
ethionamide, are common. Thyroid function returns to normal when the drug is 
discontinued. Hepatitis occurs in 0.3-0.5% of the cases, allergic reactions (fever, rash, 
and pruritus), hemolytic anemia, agranulocytosis, leukopenia, thrombocytopenia, 
malabsorption syndrome, and increased thyroid volume are rare, as are cardiovascular 
adverse effects (pericarditis), neurological adverse effects (encephalopathy), respiratory 
adverse effects (eosinophilic pneumonia), and ocular adverse effects (optic neuritis). 
PAS should be used with caution in patients with glucose-6-phosphate dehydrogenase 
(G6PD) deficiency and in those who are allergic to aspirin. (Arbex et al 2010) 
 
Drug-drug interactions 
Digoxin can reduce the absorption of PAS. Ethionamide can increase hepatotoxicity and 
hypothyroidism in patients treated with PAS. Isoniazid increases acetylation, which 
results in an increase in the serum levels of PAS. Concomitant use of angiotensin-
converting enzyme inhibitors and PAS can reduce the antihypertensive effect of the 
latter. Concomitant use of PAS and carbonic anhydrase inhibitors potentiate the 
adverse effects of both drugs, and concomitant use of PAS and systemic corticosteroids 
can also increase the number and severity of adverse effects, especially gastrointestinal 
effects. PAS can reduce the effect of loop diuretics, and, conversely, loop diuretics can 
increase the serum levels of PAS. With the exception of diclofenac, nonselective 
NSAIDS can increase the adverse effects of PAS. PAS can increase the hypoglycemic 
effects of sulfonylurea, as well as increasing the risk of bleeding when administered in 
conjunction with oral anticoagulants, thrombolytics, or salicylates. (Arbex et al 2010) 
The elimination of methotrexate, a widely used antifolate drug has been found to be 
prolonged in patients using salicylates, PAS being one of them, and sulphonamides. 
This can increase exposure to methotrexate, and may result in increased drug toxicity. 
(Joerger et al 2006) Other DDIs reported to occur between PAS and other drugs are 
listed in the table 3. 
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Table 3:  Drug-drug interactions between PAS and other medications 
Drug Interaction 
Azathioprine PAS may increase the toxicity of azathioprine. 
Mercaptopurine PAS may increase the toxicity of mercaptopurine. 
Sulindac Risk of additive toxicity (e.g. bleed risk). PAS may 
decrease the serum concentration of sulindac.  
Thioguanine PAS may increase the toxicity of thioguanine. 
Tiaprofenic acid Increased risk of gastrointestinal bleeding. 
Tolmetin Additive effects increase the risk of GI bleeding 
Trandolapril PAS may reduce the efficacy of trandolapril 
Treprostinil The prostacyclin analogue, treprostinil, may increase 
the risk of bleeding when combined with PAS.  
Warfarin The antiplatelet effects of PAS may increase the 
bleeding risk associated with warfarin. 
Adapted from http://www.drugbank.ca/drugs/DB00233. 
 
2.12.2 Ethionamide  
Thioamide drugs, ethionamide and prothionamide, have been widely used for many 
years in the treatment of mycobacterial infections caused by MTB.  Both are bactericidal 
and are essentially interchangeable in a chemotherapy regimen. They are the most 
frequently used drugs for the treatment of drug-resistant TB and, therefore, are 
becoming increasingly relevant as the number of MDR and XDR cases is increasing 
worldwide. (Wang et al 2007)  
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Pharmacokinetics 
Absorption: Approximately 80% of a gastrointestinal oral dose of ethionamide is rapidly 
absorbed from the gastrointestinal tract.  Following a single 1 g oral dose in adults, peak 
plasma concentration of ethionamide averaging 20 µg/ml are attained within 3 hours 
and less than 1 µg/ml at 24 hrs. Following a single 250 mg oral dose in adults, the peak 
plasma concentrations of ethionamide average 1-4 µg/ml (McEvoy 1990). 
  
Distribution: It is widely distributed throughout body tissues and fluids. It crosses the 
placenta and penetrates the meninges, appearing in the CSF in concentrations 
equivalent to those in the serum. (Reynolds 1989) The in vivo penetration of 
ethionamide into pulmonary macrophages and epithelial lining fluid (ELF) in humans 
has not been reported. (Conte et al 2000) 
 
Metabolism: Ethionamide is extensively metabolized, to ethionamide sulfoxide, 2-
ethylisonicotinic acid and 2-ethylisonicotinamide. The sulfoxide is the main active 
metabolite. The sulfoxide metabolite has been demonstrated to have antimicrobial 
activity against MTB. (DeBarber et al 2000) 
 
Mechanism of action 
Ethionamide may be bacteriostatic or bactericidal in action, depending on the 
concentration of the drug attained at the site of infection and the susceptibility of the 
infecting organism. Ethionamide, like prothionamide and pyrazinamide, is a nicotinic 
acid derivative related to isoniazid. It is thought that ethionamide undergoes intracellular 
modification and acts in a similar fashion to isoniazid. It inhibits the synthesis of 
mycoloic acids, an essential component of the bacterial cell wall. (DeBarber et al 2000) 
Both the drug and the sulfoxide metabolite are active against MTB. 2-ethylisonicotinic 
acid and 2-ethylisonicotinamide are not active metabolites. (Reynolds 1989) 
 
Adverse effects 
Gastro intestinal disturbances are the most frequent. Adverse effects of the drug include 
nausea, vomiting, diarrhea, abdominal pain, excessive salivation, metallic taste, 
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stomatitis, anorexia, and weight loss. These adverse effects appear to be dose related, 
with approximately 50% of patients being unable to tolerate a single dose of 1 g. (Fox et 
al 1969) Transient increases in serum bilirubin, AST and ALT concentrations have been 
reported in patients receiving ethionamide. Hepatitis (with or without jaundice) has also 
been reported. (Fajardo et al 2006) Goiter, with and without hypothyroidism, has also 
been associated rarely with ethionamide therapy. (Drucker et al 1984)  
 
2.12.3 Terizidone 
The chemical structure of terizidone consists of two molecules of cycloserine and one 
molecule of terephtalaldehyde. (Zitkova and Tousek 1974) It is a broad spectrum 
antibiotic. Terizidone capsules of 250 mg each is recommended for TB both pulmonary 
and extra pulmonary by resistant strains of MTB or avium. Terizidone is being used in 
some countries like South Africa instead of cycloserine and is assumed to be as 
efficacious; however, there are no direct studies comparing the two drugs. (WHO 
Geneva 2008) 
 
Mechanism of action 
Terizidone acts by inhibiting cell wall synthesis by competitively inhibiting two enzymes, 
L-alanine racemase and D-alanine ligase, thereby impairing peptidoglycan formation 
necessary for bacterial cell wall synthesis. (Agam 2010) 
 
Pharmacokinetics  
Terizidone is completely and rapidly absorbed after oral administration. Maximum 
concentrations in blood are achieved in 2 to 4 hrs. Excretion in urine is faster in young 
than in older patients. It is well distributed in all body fluids and tissues. The half-life of 
terizidone is significantly greater than that of cycloserine with doses of 250 mg and 500 
mg. Also, it is significantly higher in the elderly than in young patients. (Agam 2010) 
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Adverse effects  
Dizziness, slurred speech, headache and convulsions are amongst the few reported 
side effects. Others include tremors, insomnia, confusion, depression. The most 
dangerous side effect is suicidal tendency. Nausea, vomiting, skin allergies and rashes 
are also reported. When used in higher doses that are more than 1 g per day liver 
function disorders, congestive cardiac failure, convulsions and coma are reported. 
(Agam 2010) 
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CHAPTER THREE 
HYPOTHESES OF THE STUDY 
The work contained in this thesis is based on the following hypotheses: 
1. Because of developmental changes, the PK of PAS and resulting plasma levels 
may differ in children of different age groups. 
 
2. Young children require a higher body weight adjusted dosage of the “second-
line” anti-TB agent PAS than adults to achieve equivalent plasma concentrations. 
3. The drugs under investigation are metabolically unstable and have a potential for 
drug-drug interactions.  
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CHAPTER FOUR 
AIM OF THE STUDY 
The primary aim of this thesis was to evaluate the PK of PAS in children, in comparison 
to PK data obtained in adults. In the second part of the study (exploratory in vitro study), 
stability and susceptibility to biotransformation of the second-line anti-TB drugs ETH 
and PAS were determined as well as the potential of PAS, ethionamide and terizidone 
towards the inhibition of CYP450 enzyme system. The specific aims were: 
1. To document the descriptive PK of the second-line anti-TB agent PAS in 
children, in an attempt to provide an insight to the dosing rationale of this 
compound; these data were compared to the results obtained in adult patients as 
a reference group. 
2. To compare the PK profile of PAS in children when administered once versus 
twice daily. 
3. To generate baseline data and methodology for the future application of in vitro 
metabolism studies at the Division of Pharmacology. 
4. To determine the potential DDIs of ethionamide, terizidone and PAS by inhibiting 
the CYP450 isoenzymes 1A2 and 2C9. 
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CHAPTER FIVE 
MATERIALS AND METHODS 
5.1 Study subjects 
A prospective study was conducted in 22 patients who were on TB treatment at 
Brooklyn Chest Hospital (BCH), Cape Town, South Africa. BHC is a TB hospital, 
focusing on the long-term treatment of complicated and drug-resistant TB. 
The diagnosis of TB was based on clinical symptoms, X-ray examinations, sputum and 
gastric washings microscopy, and MTB culture. Patients were included if they were on 
PAS on their treatment regimen.  Patients who were below 3 months or above 60 years 
of age and those with severe anemia, vomiting and diarrhea were excluded.  
The study was conducted according to the ethical guidelines and principles of the 
International Declaration of Helsinki, South African Guidelines for Good Clinical Practice 
and the Medical Research Council (MRC) Ethical guidelines for research and was 
approved by the Human Research Ethics Committee at Stellenbosch University 
(number N09/08/212).  
Written informed consent was obtained from all subjects while in children one parent or 
a legal guardian was asked to provide written informed consent and children over 7 
years of age provided assent. PAS was prescribed by the attending pediatrician or 
physician for all patients. Exclusion criteria were severe anemia, severe diarrhea, 
severe dehydration and/or severe illness. 
5.2 Study design 
1. A prospective, longitudinal, hospital based clinical pharmacokinetic study. 
2. An in-vitro laboratory based analytical study. 
5.3 Drug administration 
All patients were prescribed oral doses of PAS (PASER granules, PAS Delayed-
Release Granules-JACOBUS) produced by Jacobus Pharmaceutical Co, Inc., 
Princeton, NJ 08540 (USA). All children received a 75 mg/kg twice daily at least 2 
weeks before enrolment into the study.  
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The study dosing regimens were adjusted on two occasions; at the first visit children 
patients received 75 mg/kg body weight twice daily and at the second visit children 
received 150 mg/kg body weight once daily, and this dose was received two days 
before the study day. All children received 75 mg/kg in between study days. However, 
they were given 150 mg/kg body weight dose for two days prior to the second visit study 
day. 
Adult patients received the standardized dose of 4 g twice daily throughout the study 
period. Adherence to PAS was monitored by direct observation.   
By necessity, concomitant drugs were allowed to vary across the patients according to 
the susceptibility pattern of each patient organism. None of the concurrent medications 
were known to have DDIs with PAS. Although breakfast typically was given to patients 
approximately 1 hr after dosing, the timing of food intake in relation to doses was not 
controlled. All doses were taken with an acidic beverage (orange juice) to prevent an 
early release of the drug in the stomach. 
5.4 Sample collection and bioanalysis of PAS 
Doses, dosing times, and blood sampling times were carefully recorded for each patient 
on a study flow sheet during each visit. For the adult patients blood was collected 
through a 20-gauge angiocatheter inserted into a forearm vein. For the pediatric 
patients a proportionate smaller angiocatheter was used.  
A total of 6 ml of blood was scheduled to be collected immediately before and at 2, 4 
and 6 hrs after drug ingestion in the first 3 patients (C1-C3) (children) and the same 
were repeated after 4 weeks of treatment. Following an interim analysis of the 
pharmacokinetic data, the protocol was amended for the subsequent patients. This 
amendment was approved by the Ethics Committee.  
The blood samples were drawn prior to taking the dose and subsequently at 2, 4, 6, 8 
and 12 hrs after ingestion of a drug on day one and the same procedure was repeated 
after 4 weeks. In the adult group, blood samples were drawn before and at 2, 3, 4, 5, 6, 
8 and 12 hrs after drug ingestion on day one; this was then repeated after two to four 
weeks.   
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Samples with accurately recorded collection times between 0 hr and 12 hrs post-dose 
were acceptable for analysis. The blood samples were centrifuged at 4000 g for 10 min 
to obtain plasma. The plasma was promptly harvested and frozen at -80˚C until assay. 
All samples were assayed in duplicate using a High Performance Liquid 
Chromatography/mass spectrometry method (LC-MS/MS) at the Division of 
Pharmacology, Department of Medicine, Faculty of Heath Sciences, Stellenbosch 
University. The details of the assays are described in table 4. 
5.5 PK analysis of PAS 
PK parameters of PAS were calculated for each subject using a non compartmental 
model with first-order absorption and first order elimination, under the assumption that 
all subjects were at steady state. The maximum concentration of drug in plasma was 
defined as Cmax and the time to this maximum concentration as Tmax, Cmax and Tmax 
were determined directly from the plasma concentration time profiles. The area under 
the plasma concentration-time curve from time 0 to T (AUC0–T), where T is the dosing 
interval, was calculated with the use of the linear trapezoidal method. Apparent oral 
clearance (CL/body weight•F) was calculated as dose/AUC0-T•body weight. 
5.6 Statistical analysis 
The identified independent variables were age, sex, body weight, size of each dose and 
concomitant medications. The mean values, median, standard deviation (SD), Standard 
error (SE), coefficient of variation and range for each parameter were calculated and the 
results were presented in tables and graphs using Stata software, Version 10, 2009 
(Stata Corp, Texas, USA) and Graph Pad Prism version 5.01. (GraphPad software, Inc, 
San Diego, California).  
A repeated measures ANOVA was performed using the MIXED procedure in SAS 
version 9 (Local, XP_PRO). The comparison between groups (adults versus children, 
children receiving 75 mg/kg or 150 mg/kg and disease state) was treated as a between 
subject effect, whereas time after intake of study drug was regarded as a within subject 
effect.  
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5.7. Materials and methods for the in vitro study 
5.7.1 Materials 
5.7.1.1 Buffers 
1. Potassium phosphate, monobasic (KH2PO4) (Sigma, St. Louis, MO). 
2. Potassium phosphate, dibasic, trihydrate (K2HPO4 · 3H2O) (Sigma, St. Louis, MO). 
5.7.1.2 Reagents for the NADPH-regenerating system 
1. Glucose-6-phoshate (Sigma, St. Louis, MO). 
2. N-Nicotinamide adenine dinucleotide phosphate, NADPH, reduced form (Sigma, St. 
Louis, MO). 
3. Sodium citrate, tribasic (Sigma, St. Louis, MO). 
4. Glucose-6-phosphate dehydrogenase (G6PDH) (Sigma, St. Louis, MO). 
5. MgCl2 · 6H2O (Sigma, St. Louis, MO). 
5.7.1.3 CYP- specific substrates and metabolites 
1. Phenacetin, a probe substrate for CYP1A2 (Sigma, St. Louis, MO). 
2. Diclofenac, a probe substrate for CYP2C9 (Sigma, St Louis, MO). 
5.7.1.4 CYP selective inhibitors 
1. Naphthoflavone, a CYP1A2 selective inhibitor (Sigma, St. Louis, MO). 
2. Quercetin, a CYP2C9 inhibitor (Sigma, St. Louis, MO). 
5.7.1.5 Human liver microsomes 
1. Pooled HLMs were obtained from XENOTECH, LLC, Kansas City, MO. Each batch 
contained the pooled HLMs from 50 different donors. All the donors were dead (e.g. 
motor traffic accidents, cerebral vascular accidents and brain death). All samples were 
from the otherwise healthy donors and in all cases the cause of death did not result 
from any known biochemical deficiency in the liver.  
5.7.1.6 Solvent, test compounds and internal standard 
1. Deionized water. 
2. Methanol. 
3. Acetonitrile. 
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4. Test compounds; PAS, terizidone, ethionamide. 
5. Thiacetazone as an internal standard (IS). 
5.7.1.7 Other materials and instruments for the analysis 
Agilent 1100 high-performance liquid chromatography (HPLC) system with an 
autosampler interfaced to an atmospheric turbulon ionisation chamber of an API 2000 
tandem mass spectrometer (MS/MS). 
5.7.2 Incubation conditions: General 
Specific aspects of incubation condition for each assay (e.g., protein concentration, 
incubation time, reaction termination solvent) are described below. HLMs were thawed 
from -80°C. In general, graded concentrations of the substrates were incubated with the 
HLMs at protein concentration of 0.25 µg/ml in potassium phosphate buffer (pH 7.4), 
and pre-warmed to 37ºC in incubation eppendorf tubes immersed in shaking water bath 
(37°C). Metabolic reactions were initiated by the addition of NADPH-regenerating 
system made of 2.6mM NADP+, 6.7 mM G6P, 6.6 mM magnesium chloride and 0.8 
units/ml G6PDH. Metabolic reactions were terminated by precipitation of microsomal 
proteins upon the addition of ice cold acetonitrile (-20°C) and centrifuged at 4042 g for 
10 minutes.  
5.7.3 Determination of kinetic parameters in microsomal incubation 
To determine the kinetic parameters for CYP-specific substrates, incubation conditions 
were first optimized. In the current method (Yan and Caldwell 2004) the final 
concentration of microsomal proteins was 0.25 mg/ml, and incubation time was 30 
minutes. The concentration range of a particular substrate was estimated according to 
Km values in the literature. Briefly, a CYP-specific substrate compound at different 
concentrations was mixed with microsomes. After a 5 minutes preincubation period, an 
NADPH-regenerating solution was added to initiate the reaction. The reaction was 
stopped by the addition of ice cold acetonitrile. The compound remained after a specific 
CYP-catalyzed oxidation were analyzed using LC-MS/MS. 
5.6.3.1 Substrate working solutions 
1. Microfuge tubes were labeled. 
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2. The substrate stock solution was diluted with deionized water to the highest desired 
concentration. 
3. 400 ml of deionized water was added to each of tube. 
4. 200 ml of substrate solution was transferred to the microfuge tubes and was mixed by 
vortexing. 
5.7.3.2 Microsomal dilutions 
1. To make a 13 ml microsomal solution, 2.6 ml 0.5 M potassium phosphate, (pH 7.4) 
was added to a 15 ml tube. 
3. 325 ml HLMs was added (20 mg/ml proteins). 
4. Deionized water was supplied to bring to the desired volume (13 ml). 
5. The tube was inverted repeatedly to mix all components and was kept on ice. 
5.7.3.3 NADPH- regenerating solution 
In the current method, a NADPH-regenerating solution was prepared as described 
below, which contained 2.6 mM NADP+, 0.8 U/ml G6PDH, 6.7 mM glucose-6-
phosphate, and 6.6 mM magnesium chloride. 
1. 2.6 ml of 0.5 M of potassium phosphate, pH 7.4, was transferred to a 15-ml tube. 
2. 8.84 ml deionized water was added to the tube. 
3. 1.3 ml stock solution of cofactors was added. 
4. 0.26 ml of G6PDH solution (40 U/ml) was added to complete the NADPH-     
regenerating system right before use. 
5.7.3.4 Microsomal incubation 
1. 10 ml of substrate was dispensed at different concentrations to corresponding 
incubation tubes. 
2. 250 ml of diluted HLMs was dispensed to each tube using a pipette. 
3. Preparation of NADPH-generating solution was completed by adding the G6PDH 
solution. 
4. With a use of a pipette, 240 ml NADPH-generating solution was dispensed to each 
tube to initiate the reaction. 
5.  1 ml ice-cold acetonitrile was used to stop the reaction. 
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6. The preparation was then centrifuged for 10 min at 4000 g to pellet down microsomal 
proteins. 
7. The supernatant was transferred to HPLC vials for LC-MS/MS analysis. 
 
5.7.3.5 Determination of IC50 values in HLMs 
After kinetic parameters of a CYP-specific substrate were determined, an experiment 
was performed to measure the IC50 value of a test compound for this particular CYP 
enzyme. Basically, a test compound was serially diluted to desired concentrations and 
then mixed with microsomes containing a CYP-specific substrate at a concentration 
equal or close to the Km value of the substrate determined under optimal conditions. 
After incubation with NADPH, the effect of the test compound on the CYP marker 
activity was then evaluated by measuring the remainder of the CYP substrate. For the 
quality control, CYP selective inhibitors were also included in the assay. 
5.7.3.6 Preparation of known CYP inhibitors 
Individual CYP-selective inhibitors were used to initially validate the inhibition assay 
when the assay was established and to verify the assay as positive controls. 
1. Naphthoflavone, 0.1 mM dissolved in acetonitrile. 
2. The CYP-specific inhibitors in tube were diluted to the desired concentration. 
5.7.3.7 Test compound solutions 
1. The test compounds were dissolved in an appropriate solvent to prepare a 10 mM 
solution. 
2. Microfuge tubes were labeled accordingly 
3. The compound stock solution was transferred to the appropriate tube. 
4. Solvent (used to dissolve the compound) was added to each of tubes. 
5. The compound stock solution was transferred to the tube and was mixed by 
vortexing.  
6. Serial dilution (fourfold dilution) of compound in tubes was then performed. 
7. Solvent alone was used as negative control.  
8. A CYP-specific inhibitor was used as positive cont 
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5.7.3.8 Inhibition assay  
1. NADPH-regenerating solution and the test compound were prepared as described 
previously. 
2. 5 µl of test compound was dispensed at different concentrations to corresponding 
tubes.  
3. 245 µl of diluted HLMs solution was added to each tube. 
6. 240 µl of NADPH-generating solution was added to each tube. 
7. The mixture was incubated in a 37°C water bath for 5 min. 
8. 10 µl of CYP-specific substrate was added to each tube, and incubation was 
continued for an additional 30 min. 
9. Ice-cold acetonitrile was added to stop the reaction. 
10. The mixture was centrifuged for 10 min at 4000 g. 
11. The supernatant was transferred to HPLC vials for LC-MS/MS analysis, as 
described below. 
 
5.8 Analytical methods 
The developed analytical procedures (methods) were aimed to serve for a research 
project.  All procedures were performed as accurately as possible, guidelines as laid 
down by the FDA and EMA were adhered to as far as possible. A full validation of the 
methods, as laid down by the FDA and/or EMA for clinical trials conducted by the 
pharmaceutical industry, was however not possible within the scope of the Division of 
Pharmacology. 
Blood samples were collected in 1.0 ml sampling EDTA containing sampling vials and 
centrifuged at 3500 g for 5 minutes to separate plasma and cellular matter. Collected 
plasma samples were frozen at -80oC and stored until analysis. The stability of 
compounds under investigation in frozen samples was determined over a time period of 
6 months; no degradation could be detected within this time period. 
Patient samples were analyzed within this time window, usually within 3 weeks after 
collection. Freezing and thawing of samples did not significantly influence the 
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concentrations of high, medium and low calibrators of the compounds under 
investigation. 
To 100 µl of plasma 300 µl of methanol, containing 1.0 µg/ml thiazetazone (IS) (Sigma, 
St Louis, USA), was added to precipitate plasma proteins.  Samples were centrifuged at 
11 000 g for 5 minutes. 250 µl of the supernatant was transferred into suitable 
autosampler vials for analysis. The temperature of the autosampler was set to be 6 oC.  
The respective injection volumes are indicated in table.  
Specimens were analyzed using a binary HPLC (Agilent Series 1100 HPLC, Agilent 
Technologies, Waldbronn, Germany) equipped with an Agilent Zorbax analytical column 
( 150 mm x 2.1 mm (ID), 3.5 µm particle size. The column temperature and flow rate are 
indicated for each compound in the table below. The mobile hydrophilic phase “A” was 
water containing 0.1% formic acid (FA) (Fluka Chemie GmBH, Buchs, Switzerland) 
whilst the lipophilic phase “B” was either methanol or acetonitrile (E. Merck, Darmstadt, 
Germany) both containing 0.1% FA. All solvents were of HPLC grade and were filtered 
through a 0.45 µm filter to remove possible particular matter. The respective used 
gradients are indicated below. Specifications of the pure compounds to create 
respective calibration curves are indicated in table 4. In all instances a quadratic 
equation was used for calibration including a 1/x weighting resulting in an R2 value of 
better than 0.9900.  
The concentration of the compounds was determined by means of an API 2000 tandem 
Mass Spectrometer (MS/MS) (Applied Biosystems, MDS Sciax, Foster City, Canada) 
equipped with an atmospheric turbulon ionization chamber. A single quantifier transition 
range for the IS (thiazetazone) with a precursor and product ion of m/z 237.12 / 119.96 
(dwell 500 msec) was used whilst a transition of m/z 237.12 / 134.10 (dwell 500 msec) 
was used as qualifier. The retention time of thiazetazone was 7.0 min. A switching valve 
was used to only introduce the column effluent into the nebulizing chamber at specified 
time ranges including the time from 6.5 to 7.5 min for the IS to avoid unnecessary 
contamination of the nebulising chamber.  
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To each sample batch 8 calibrators of varying concentrations were included into the run 
as quality control (QC) samples.  
For all compounds a variation of less than ± 5% was found over the entire duration of 
the analysis. Duplicates of patient samples did not vary more than 2.5% from each 
other. Intraday variation was less than 3% whilst day to day variation was found to be 
less than 5% over the respective calibration range. 
The quantifier m/z transition was used for quantification whilst the indicated qualifier m/z 
transition was used to ensure selectivity of the respective compound. The respective 
m/z transitions are listed in table 4. 
Table 4: Summary of bioanalytical methods 
Drug specific 
individual instrument 
settings 
 
Phenacetin 
 
Diclofenac 
 
PAS 
Pure compound 
specifications used for 
calibration and creation 
of respective standard 
curve 
Aldrich, Cat # 
77440 
Lot S84263 - 289 
Sigma, Cat # D-
6899 
Lot 100K1715  
Aldrich, Cat # A7,960-4 
Lot : S 44855 - 149 
Solvents with  
0.1% FA added 
A: Water 
B: Acetonitrile 
A: Water 
B: Methanol 
A: Water 
B: Methanol 
Gradient of Solvents 
A(hydrophilic):B(organic) 
Time range /  (% A)  
0.0-1.0 / 65% A 
1.0-1.1 /1.0% A 
1.1-5.5 / 1% A  
5.5-5.6 / 65% A 
5.6-10.0 / 65% A 
0.0-1.0 / 50% A 
1.0-2.0 / 5% A 
2.0-8.0 / 5% A 
8.0-8.10 / 50% A 
8.1-11.0 / 50% A 
0.0-0.95 / 90% A 
0.95-1.0 / 10% A 
1.0-8.0 / 10% A 
8.1-12.5 / 90% A 
Injection volume 2.5 µl 2 µl 5 µl 
Flow speed 300 µl / min 300 µl / min 300 µl / min 
Column  temperature 40 oC 40 oC 40 oC 
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Nebulizing temp. 375 oC 375 oC 375 oC 
Mode Positive mode Negative mode Positive mode 
Quantifier transition 
(m/z) 
180.2 / 110.1 293.88 / 249.00 154.2 / 136.2 
Qualifier transition(s) 
(m/z) 
180.2 / 138.1 No qualifier with a 
suitable intensity 
154.2 / 119.2 and 
154.2 / 108.2 
Dwell time (msec) 400 msec 300 msec 500 msec 
Retention time 3.35 min 6.65 min 5.42 min 
Switching valve settings 2.5 to 4.5 min 6.0 to 8.0 min 4.5 to 6.0 min 
Lower limit of detection 0.1 µg/ml 0.25 µg/ml 0.25 µg/ml 
Calibration range 0.25 to 75.0 µg/ml 1.0 to 100 ug/ml 1.0 to 100.0 µg/ml 
*FA : Formic acid 
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CHAPTER SIX 
RESULTS 
6.1 Pharmacokinetics of PAS in children 
6.1.1 Patient baseline characteristics 
Twenty two TB patients were included in this study. Demographic characteristics (age, 
body weight, sex, height and HIV status) are presented in table 5. Among these 
patients, ten were children, their mean age was 4.2 years (range: 1 to 12 years) and 
three (30%) were male. Mean body weight was 14.8 kg (range: 5.4 to 26.6 kg. Mean 
height was 93.4 cm (range: 60 to 130 cm). Four (40%) patients were HIV-positive, and 
epilepsy was found in one patient (10%). Twelve patients were adults, mean age was 
31.3 years (range: 18 to 53 years). Four patients were male (33.3%). Mean body weight 
was 63.4 kg (range: 37 to 84 kg). Mean height was 169.8 cm (range: 163 to 183 cm). 
Four (33.3%) patients were HIV-positive and epilepsy was found in one patient (8.3%). 
At least one first line anti-TB drugs was used by each of the patients, these included 
isoniazid, pyrazinamide and ethambutol. However, rifampicin was not among the drugs 
used by any of the patients. All patients received similar SLDs, these included the 
fluoroquinolone ofloxacin, the thionamide ethionamide, terizidone and the 
aminoglycoside capreomycin. One patient received rimactazide and one was on 
linezolid as part of the TB regimen.  
All HIV positive patients were on an ART, which included stavudine, lamivudine and 
efavirenz, except for one adult patient who was on a zidovudine containing regimen. 
Two patients (one child and one adult) were epileptic; they received sodium valproate 
and haloperidol, respectively. The detailed information on concomitant medications for 
each individual patient is presented in tables 5 and 6. 
All patients were studied on two occasions as planned. All PK assessments were 
completed without any events (e.g. vomiting) that may have affected the PK profiles that 
were recorded. 
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Table 5: Individual patient characteristics: Children (N=10) 
Subject Age 
(yrs/months) 
Age Sex Weight 
(kg) 
Z-score Diagnosis Concomitant 
Medications 
C1 3/1 3 F 13 -1.04 XDR-TB PZA, TZ, ETH, 
RIMACT, CAPRE. 
C2 4/9 5 F 18 0.09 XDR-TB, 
HIV 
INH, PZA, ETHA, 
ETH, TZ, OFLOX, 
D4T, 3TC, EFV. 
C3 3/8 4 M 18  0.30 XDR-TB INH, PZA, TZ, 
ETH, OFLOX. 
C4 12/7 3 M 27  -2.32 XDR-TB, 
HIV, 
EPILEPSY 
INH, PZA, TZ, 
ETH, D4T, 3TC, 
EFZ, SOD. VAL, 
LINEZ. 
C5 9/1 9 F 25 -0.90 XDR-TB, 
HIV 
INH, PZA, ETHA, 
ETH, OFLOX, 
D4T, 3TC, EFV. 
C6 1/9 2 F 11 -1.00 XDR-TB INH, PZA, ETH, 
TZ, OFLOX. 
C7 3/8 4 F 15.5 -0.18 XDR-TB, 
HIV 
INH, PZA, TZ, 
OFLOX, 3TC, 
EFV, D4T. 
C8 0/10 1 M 8 -1.74 XDR-TB INH, PZA, ETHA, 
TZ, ETH, OFLOX. 
C9 1/0 1 F 9 -3.95 XDR-TB INH, PZA, ETHA, 
TZ, OFLOX, 
CAPRE. 
C10 1/8 1 F 13 -3.15 XDR-TB INH, PZA, ETHA, 
TZ, ETH, OFLOX, 
CAPRE. 
INH: Isoniazid, PZA: Pyrazinamide, ETHA: Ethambutol, ETH: Ethionamide, TZ: 
Teridizone, OFLOX: Ofloxacin, CAPRE: Capreomycin, RIMACT: Rimactazide, LINEZ: 
Linezolid, D4T: Stavudine, 3TC: Lamivudine, EFV: Efavirenz, AZT: Zidovudine, 
SOD.VAL: Sodium valproate.  
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Key: 
Classification Z-score value 
Normal -2.0 < Z-score 
Moderately malnourished -3.0 < Z-score < -2.0 
Severely Malnourished Z-score < 3.0 or oedema 
Nutrisurvey2007.exe 
The Z-score is an indicator for how many standard deviations the child is above or 
below the mean. A z-score of less than -2 or more than +2 is usually seen as out of the 
normal range. 
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Table 6:  Individual patient characteristics: Adult patients (N=12). 
Subject Age Sex 
(yrs) 
Weight 
(kg) 
Height  
(cm) 
BMI Diagnosis Concomitant Medications 
A1 31 F 84 165 30.7 XDR-TB, 
HIV 
INH, PZA, TZ, ETHA, ETH, 
OFLOX, D4T, 3TC, EFV. 
A2 27 F 59 163 22.2 XDR-TB, 
HIV 
INH, PZA, ETHA, ETH, TZ, 
OFLOX, CAPRE, D4T, 3TC, 
EFV. 
A3 27 F 72 173 24.1 XDR-TB, 
HIV 
INH, PZA, ETHA, TZ, ETH, 
OFLOX, CAPRE, D4T, 3TC, 
EFV. 
A4 18 F 45 164 16.7 XDR-TB, 
HIV, 
EPILEPSY 
INH, PZA, TZ, ETH, D4T, 
3TC, EFZ, EPIL, LINEZ. 
A5 26 F 38 161 14.5 XDR-TB, 
HIV 
INH, PZA, ETHA, OFLOX, 
CAPRE, D4T, 3TC, EFV. 
A6 53 M 74 183 21.9 XDR-TB, 
HIV 
INH, PZA, ETH, TZ, OFLOX, 
CAPRE, D4T, 3TC, EFV. 
A7 19 F 55 167 19.7 XDR-TB PZA, ETHA, ETH, TZ OFLOX, 
CAPRE. 
A8 34 F 58 169 20.1 XDR-TB PZA, ETHA, TZ, ETH, 
OFLOX, CAPRE. 
A9 41 M 76 175 24.8 XDR-TB PZA, ETHA, TZ, OFLOX, 
CAPRE. 
A10 48 M 70 170 24.8 XDR-TB PZA, ETHA, TZ, ETH, 
OFLOX. 
A11 30 M 71 178 24.2 XDR-TB, 
HIV 
PZA, ETHA, ETH, OFLOX, 
CAPRE, D4T, 3TC, EFV, AZT, 
HAL. 
A12 21 F 62 169 21.5 XDR-TB INH, PZA, TZ, OFLOX. 
INH: Isoniazid, PZA: Pyrazinamide, ETHA: Ethambutol, ETH: Ethionamide, TZ: 
Teridizone, OFLOX: Ofloxacin, CAPREO: Capreomycin, RIMACT: Rimactazide, LINEZ: 
Linezolide, D4T: Stavudine, 3TC: Lamivudine, EFV: Efavirenz, AZT: Zidovudine, HAL: 
Haloperidol, BMI: Body mass index. 
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BMI Categories:  
Underweight: 18.5, Normal weight: 18.5 - 24.9, Overweight: 25 - 29.9, Obesity: BMI of 
30 or greater. 
Table 7:   Summary of patient characteristics at the time of the PK assessment 
(average for both visits) 
Characteristics Children (N=10) Adults (N=12) 
Age - yr   
  Mean 4.2 31.3 
  Median 4 28.5 
  Range 1-12 18-53 
  SD 2.5 11.1 
Weight - kg   
  Mean 14.8 63.4 
  Median 14.2 66 
  Range 5.4-26.6 37-8 
  SD 7.3 13.4 
Height - cm   
  Mean 93.4 169.8 
  Median 93 169 
  Range 60-130 163-183 
  SD 23.6 6.5 
Male sex - No. (%) 3 (30) 4 (33.3) 
HIV positive - No. (%) 4 (40) 4 (33.3) 
SD: Standard deviation 
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6.1.2 PK of PAS in children and adults  
Complete sets of plasma specimens were obtained during treatment with PAS, given as 
a twice versus once daily dosage. Plasma concentration-time profiles for PAS after 
treatment with 75 mg/kg twice daily, 150 mg/kg once daily and 4 g twice daily are 
depicted in figures 2 and 3. Because of the small sample size plasma profiles for each 
patient (each visit) are displayed. For the initial three patients (C1-C3), blood samples 
were taken at only three time points up to 6 hours after dosing. After availability of the 
data, it was decided to change the sampling schedule to six sampling time points up to 
twelve hours after dosing. The PK parameters of PAS for adults and children on both 
study days are presented in tables 6-9. 
6.1.2.1 PK of PAS in children 
Children were given PAS once a day (150 mg/kg) or twice a day (75 mg/kg). The results 
for the 75 mg/kg twice daily dosing regimen were: Geometric mean Cmax was 45.4 µg/ml 
(range: 3.8-68.1), geometric mean Tmax was 4.8 hrs (range: 0-8), PAS exposure, as 
measured by the geometric mean AUC was 233.3 µg•h/ml (range: 22.1-46.1) and mean 
CL/F was 10.4 l/h/kg (range: 1.3-52). 
Results for 150 mg/kg once daily dosing regimen were: Geometric mean Cmax was 56.5 
µg/ml (range 3.7-115), geometric mean Tmax was 4.8 hrs (range: 0-12), PAS exposure, 
as measured by the mean AUC was 277.9 µg•h/ml (range: 14.1-702) and mean CL/F 
was 47.1 l/h/kg (range: 2.2-283.1). The mean 12 hr concentration following the 75 
mg/kg dose in the children was 6.8 µg/ml (range: 0.7-19.4) compared to 21.3 µg/ml 
(range: 0.6-76.7) following a dose of 150 mg/kg.  
In this study 9/10 (90%) of children attained baseline plasma levels above MIC (1 µg/ml) 
after the dose of 75 mg/kg twice daily while only 6/7 children were above MIC at 12 hr 
plasma levels. In contrast 6/10 (60%) children reached the baseline plasma levels 
above 1 µg/ml after the dose of 150 mg/kg once daily and only 5/7 (71.4%) children 
were above MIC at 12 hr mark. However, it is worthwhile to note that only 7 out of 10 
children were subjected to the 12 hr measurements as described in the methodology 
section. Individual concentrations, mean values and standard deviations are presented 
in table 8. 
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Table 8: Pharmacokinetic parameters in 10 children after oral administration of twice 
daily dosage of 75 mg/kg of PAS 
Subject Dose 
(mg) 
 Cmax 
(µg/ml) 
12 h 
(µg/ml) 
Tmax (h) AUC0-T 
(µg•h/ml) 
CL/F (l/h/kg) 
1 1000  31.8 * 6 59.6 * 
2 1340  53.4 * 4 227.1 * 
3 1260  39.1 * 4 213.7 * 
4 2000  82.7 10.9 0 395.3 5.1 
5 1870  54.8 7.2 2 320.8 5.8 
6 0780  36.3 1.0 6 197.9 3.9 
7 1150  3.8 1.7 8 22.1 52.0 
8 0590  26.1 6.5 8 191.1 3.1 
9 0400  57.9 0.7 4 245.0 1.6 
10 0580  68.1 19.4 6 461.1 1.3 
Mean 1097  45.4 6.8 4.8 233.3 10.4 
Range 400-
2000 
 3.8-68.1 0.7-
19.4 
0-8 22.1-
461.1  
1.3-52 
Median 1075  46.3 6.5 5.0 220.4 3.9 
SD 539.7  22.7 6.7 2.5 135.1 18.4 
SE 170.7  7.2 8.3 0.8 42.7 6.9 
CV (%) 49.2  49.9 1.0 52.7 57.9 177.0 
* The value was either not available or could not be calculated due to insufficient blood 
sampling time points, AUC0-T: area under the concentration-time curve from 0 to time 
post dose, Cmax: maximum concentration, Tmax: time to maximum concentration, CL/F: 
oral total clearance SD: standard deviation; SE: standard error, CV: coefficient of 
variation. 
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Table 9: Pharmacokinetic parameters in 10 children after oral administration of once 
daily dosage of 150 mg/kg of PAS 
Subject Dose 
(mg) 
 
 
Cmax 
(µg/ml) 
12 h 
(µg/ml) 
Tmax (h) AUC0-T 
(µg•h/ml) 
CL/F (l/h/kg) 
1 2000  65.6 * 4 105.8 * 
2 2800  78 * 4 222.5 * 
3 2700  115 * 4 471.6 * 
4 4000  3.7 1.4 0 14.1 283.1 
5 3860  83.9 76.7 8 702 5.5 
6 1690  45.3 45.3 12 298 5.7 
7 2330  51.8 0.6 0 140.6 16.6 
8 1200  20.3 2.1 6 94.3 12.7 
9 0800  36.1 0.7 4 201.8 3.9 
10 1170  65.3 21.9 6 527.9 2.2 
Mean 2255  56.5 21.2 4.8 277.9 47.1 
Range 800-
4000 
 3.7-115 0.6-76.7 0-12 14.1-702 2.2-283.1 
Median 2165  58.5 2.1 4 212.2 5.7 
SD 1101  32.4 29.6 3.6 221.3 104.2 
SE 348.2  10.3 16 1.1 69.9 39.4 
CV   48.8  57.4 1.4 74 79.7 221 
* The value was either not available or could not be calculated due to few time points, 
AUC0-T: area under the concentration-time curve from 0 to time post dose, Cmax: 
maximum concentration, Tmax: time to maximum concentration, CL/F: oral total 
clearance, SD: standard deviation, SE: standard error, CV: coefficient of variation. 
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6.1.2.2 Individual plasma concentrations of PAS in children 
Although PAS plasma concentrations from all subjects were pooled and analyzed 
together, the actual plasma concentrations in each individual patient were expressed to 
allow the better graphical presentations of common patterns of PAS variability in the 
study population (figures 3 and 4). The significant finding for both groups was that there 
was a considerable inter- and intra individual variations in the plasma profile of PAS. 
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Figure 3: Plasma concentration-time profiles following administration of PAS in two 
different doses (75 mg/kg twice daily and 150 mg/kg once daily) in individual patients 
(children). 
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6.1.2.3 PK of PAS in adults 
Adults were given a standard dose of 4 g PAS twice daily. Results for the first visit using 
a 4 g twice daily dosing regimen were: Geometric mean Cmax was 51.3 µg/ml (range: 
25.8-93.1), geometric mean Tmax was 5.2 hrs (range: 0-8), PAS exposure, as measured 
by the geometric mean AUC was 368 µg•h/ml (range: 146.5-853.3) and mean CL/F was 
13.2 l/h/kg (range: 7-27.3).  
On the second visit, using the same 4 g twice daily dosing regimen, the results were: 
Geometric mean for Cmax was 37.6 µg/ml (range: 15.7-69.5), geometric mean Tmax was 
5.2 hrs (mean: 2-8), PAS exposure, as measured by the geometric mean AUC was 
230.6 µg•h/ml (range: 64.9-539.5) and mean CL/F were 23.9 l/h/kg (range: 7.4-61.6).  
The mean 12 hrs concentration following the 4 g dose in the adults was 19.7 µg/ml 
(range: 1.8-91.5) on the first visit compared to 13.8 µg/ml (range: 2.3-34.3) on the 
second visit. 
Although the baseline plasma levels were all above MIC (1µg/ml) after the dose of 4 g 
twice daily in the first visit, 2 (16.7%) patients were below MIC on the second visit. All 12 
patients attained plasma levels above MIC at 12 hr mark in both first and second visits. 
Individual concentrations mean values, medians, standard error, coefficient of variation 
and standard deviations have been given in table 10. 
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Table 10: Pharmacokinetic parameters obtained from 12 adults after oral administration 
of 4 g of PAS (first visit) 
Subject Dose 
(mg/kg) 
Cmax 
(µg/ml) 
12 h 
(µg/ml) 
Tmax (h) AUC0-T 
(µg•h/ml) 
CL/F 
(l/h/kg) 
1 47.6 25.8 1.8 6 146.5 27.3 
2 68 48.9 8.8 5 294.3 13.6 
3 55.9 38.8 4.1 5 241 16.6 
4 88.9 38.8 7.6 5 241 16.6 
5 105.3 48.4 9.1 5 294.2 13.6 
6 54.8 93.1 91.5 8 853.3 4.7 
7 72.7 48.9 8.8 5 294.2 13.6 
8 70.2 37.3 12.3 6 310.8 12.9 
9 52.6 87.1 37.2 5 570.2 7 
10 57.1 44.7 15.8 8 324.4 12.3 
11 56.3 61.1 16.8 4 543 7.4 
12 65.6 42.8 29.4 0 303.1 13.2 
Mean 66.3 51.3 19.7 5.2  368 13.2 
Range 47.6-105.3 25.8-93.1 1.8-91.5    0-8   146.5-853.3 7-27.3 
Median 61.4 46.5 9.0 5      298.7 13.4 
SD 16.7 20.0 27.1 2      194 5.8 
SE 4.8 5.8 8.8  0.6      56 1.7 
CV (%) 25.2 39.1 1.4   39.4         52.7 43.7 
AUC0-T: area under the concentration-time curve from 0 to time post dose, Cmax: 
maximum concentration, Tmax: time to maximum concentration, CL/F: oral total 
clearance, SD: standard deviation, SE: standard error, CV: coefficient of variation. 
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Table 11: Pharmacokinetic parameters obtained from 12 adults after oral administration 
of 4 g of PAS (second visit)  
Subject Dose 
(mg/kg) 
 Cmax 
(µg/ml) 
12 h 
(µg/ml) 
Tmax (h) AUC0-T 
(µg•h/ml) 
CL/F (l/h/kg) 
1 48.2  35.8 34 8 268.0 14.9 
2 66.7  32.5 19.8 0 164.7 24.3 
3 55.6  38.0 6.8 4 248.6 16.1 
4 88.9  40.3 3.6 4 176.0 22.7 
5 108.1  21.1 6.6 8 103.1 38.8 
6 54.1  52.7 16 8 285.0 14.0 
7 72.7  29.0 4.8 4 172.4 23.2 
8 68.9  16.4 5.4 8 109.2 36.6 
9 52.6  69.5 29 5 539.5 7.4 
10 57.1  50.3 2.5 5 230.1 17.4 
11 57.1  50.3 34.3 6 406.0 9.9 
12 64.5  15.7 2.3 2 64.9 61.6 
Mean 66.2  37.6 13.8 5.2 230.6 23.9 
Range 48.2-108.1  15.7-69.5 2.3-34.3 2-8 64.9-539.5 7.4-61.6 
Median 60.8  36.9 6.7 5 203.1 20.1 
SD 17.2  16.2 12.5 2.6 134.8 15.2 
SE 4.9  4.7 34 0.7 38.9 4.4 
CV (%) 25.9  43.0 0.9 50.1 58.5 63.7 
 AUC0-T: area under the concentration-time curve from 0 to time post dose, Cmax: 
maximum concentration, Tmax: time to maximum concentration, CL/F: oral total 
clearance, SD: standard deviation, SE: standard error, CV: coefficient of variation. 
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Figure 4: Plasma concentration-time profiles following administration of PAS (4 g twice 
daily) given at steady state at two different visits in adult patients. 
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6.1.2.4 Comparison analysis 
Comparison between the first and second visits 
The mean values as well as individual patient plasma concentrations indicated a 
considerable discrepancy between the two visits. In the group of children the mean 
plasma concentrations of PAS differed between two visits but were not statistically 
significant with the P-value of 0.33. Although adults received a similar dose for each 
visit a higher plasma concentration was noted during the first visit. The difference 
between both visits was not statistically significant with the P-value of 0.82.  
Comparison between children and adults 
The results indicated that adult patients attained higher plasma concentrations when 
compared to children on the first visit when children received a 75 mg/kg dose. The 
same was noted when comparing the plasma concentrations between adults and 
children at the second visit when children received a 150 mg/kg dose. These 
differences were not statistically significant with the P-value of 0.74. 
Comparison between HIV positive and HIV negative patients 
Because of the presence of the HIV positive patients in the study population who were 
on the ART, the comparison was made between HIV positive and HV negative patients 
from both groups. The results revealed that there were no significant PK differences 
between HIV positive and HIV negative patients.  
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Mean plasma concentration against time
Comparison between first and second visits
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Figure 5: Mean steady-state plasma concentration-time profiles of PAS in children and 
adults. Children (N=10) received a dose of 75 mg/kg twice daily on the first visit and 150 
mg/kg once daily on the second visit. Adults (N=12) received a dose of 4 g PAS on both 
visits. Vertical bars denote 95 % confidence intervals. 
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Mean plasma concentration against time
Comparison between children and adults (first visit)
 Children
 Adults
0 2 4 6 8 12
Time in hours
-20
-10
0
10
20
30
40
50
60
M
e
a
n
 P
la
s
m
a
 C
o
n
c
e
n
tr
a
ti
o
n
 (
m
ic
ro
g
ra
m
 p
e
r 
m
l)
 
Figure 6: Mean steady-state plasma concentration-time profiles of PAS in children (75 
mg/kg twice daily) and adults (4 g twice daily, first visit). Vertical bars denote 95% 
confidence intervals. 
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Mean plasma concentration against time
Comparison between children and adults (second visit)
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Figure 7: Mean steady-state plasma concentration-time profiles of PAS in children (150 
mg/kg once daily) and adults (4 g twice daily, second visit). Vertical bars denote 95% 
confidence intervals. 
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Mean plasma concentration against time
Comparison between HIV statuses among children
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Figure 8: Mean steady-state plasma concentration-time profiles of PAS in HIV negative 
and HIV positive children. Vertical bars denote 95% confidence intervals. 
 
 
 
 
Stellenbosch University  http://scholar.sun.ac.za/
 61 
 
Mean plasma concentration against time
Comparison between HIV statuses among adults
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Figure 9: Mean steady-state plasma concentration-time profiles of PAS in HIV negative 
and HIV positive adult patients. Vertical bars denote 95% confidence intervals. 
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6.2 In vitro metabolism study 
In this part of the work, the CYP interaction potential of PAS, terizidone and 
ethionamide towards the CYP isoforms (CYP1A2 and CYP2C9) has been assessed. 
The source of variability and inaccuracy resides with the fact that the assays were not 
performed in duplicates because of the exploratory nature of the study. 
The Michaelis-Menten equation 
The Michaelis-Menten equation was plotted to describe the relationship between the 
rates of substrate conversion by an enzyme to the concentration of the substrate. In this 
equation, V is the rate of conversion, Vmax is the maximum rate of conversion, [S] is the 
substrate concentration, and Km is the Michaelis-Menten constant.  The Michaelis-
Menten constant is equivalent to the substrate concentration at which the rate of 
conversion is half of Vmax.  Km approximates the affinity of enzyme for the substrate.  
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Figure 10: Michaelis-Menten plot depicting the Km of phenacetin (substrate for 
CYP1A2). 
 
6.2.1 In vitro CYP1A2 inhibition by PAS, ethionamide and terizidone 
The effects of specific inhibitor on phenacetin metabolism, a marker substrate for 
CYP1A2 metabolism (substrate loss) were investigated in parallel with the test 
compounds (PAS, terizidone and ethionamide).  
The metabolism of phenacetin was shown to be inhibited by quercetin by 100% 
(positive control). For the test compounds, PAS, terizidone and ethionamide, the 
inhibition was investigated at concentrations up to 200 µM. Over this concentration 
range there was no significant inhibition by any of the test compounds as shown in 
figure 11. 
Vmax = 4.9 
   Km = 35.3 
Stellenbosch University  http://scholar.sun.ac.za/
 64 
 
0
20
40
60
80
100
P
e
rc
e
n
ta
g
e
 o
f 
In
h
ib
it
io
n
0 50 100 150 200
Concentration of Inhibitors (microgram/ml)
Quercetin PAS Terizidone Ethionamide
Quercetin PAS Terizidone Ethionamide
Inhibition of Phenacetin metabolism
 
Figure 11: Percentage inhibition of CYP1A2 dependent phenacetin metabolism by 
quercetin and the test compounds, PAS, terizidone and ethionamide. 
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Figure 12: Michaelis-Menten plot depicting the Km of diclofenac, a substrate for 
CYP2C9. 
6.2.3 In vitro CYP2C9 inhibition by PAS, ethionamide and terizidone 
The effects of specific inhibitor (quercetin) on diclofenac, a known substrate for CYP2C9 
metabolism (substrate depletion) were investigated in parallel with the test compounds 
(PAS, terizidone and ethionamide).  
The metabolism of diclofenac was clearly inhibited by quercetin by 100%. The inhibition 
was investigated at concentrations up to 200 µM of the test compounds. Over this 
concentration there was no significant inhibition by the any of the test compounds as 
shown in figure 13. 
Vmax = 1.3 
   Km = 7.5 
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Figure 13: Percentage of inhibition of the known inhibitor quercetin versus the three test 
compounds (PAS, terizidone and ethionamide) on CYP2C9 dependent diclofenac 
metabolism.  
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CHAPTER SEVEN 
DISCUSSION 
7.1 PK of PAS in children  
PAS was the first effective anti-TB agent to be administered to a child (Lehman 1964) 
and, after the introduction of streptomycin and isoniazid, PAS became an integral part of 
a standard regimen to treat TB until around 1970 when rifampicin and pyrazinamide 
were introduced. PAS was particularly valued for its role in preventing resistance to 
companion drugs. PAS became unpopular due its adverse effects and the advancement 
of newer drugs which were more effective with fewer side effects. 
With the current trends of MDR and XDR-TB, PAS has become an important 
component for treatment of resistant TB particularly XDR-TB. The introduction of PAS 
has been inevitable despite the fact that there is a paucity of information on the PAS 
usage in children. 
Preparations available: PAS preparation used in this study (Paser granules) is a 
delayed release preparation specifically designed to provide sustained, relatively low 
concentrations of PAS on the supposition that PAS is bacteriostatic in action and 
prolonged concentrations above MIC are of more importance the peak blood 
concentrations. An enteric coating protects the preparation in the acid environment of 
the stomach, but allows the rapid dissolution of the capsule within the neutral conditions 
of the small intestine.  Previously PAS was available as sodium, potassium or calcium 
salts or as aminosalicylic acid; absorption from the salts is rapid and complete, but from 
the free acid is incomplete resulting in only 77% of the dose being absorbed. (Wan et al 
1974)  
Single dose versus several daily doses:  Current practice is to aim for sustained 
concentrations of PAS above the MIC for MTB of approximately 1 µg/ml throughout the 
dosing interval. This is also thought to reduce the intolerance to PAS, which is a 
significant deferent to consistent compliance. (Peloquin 1999) In an early British Medical 
Research Council study, INH was accompanied by two possible dosages of INH, either 
10 mg/kg daily in two 5 mg/kg dosages or 20 mg/kg daily in four 5 mg/kg dosages; on 
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evaluation at 3 months 75% of 73 patients and 73% of 67 patients respectively were 
sputum culture negative indicating that increasing the total daily dosage given 
intermittently did not improve efficacy. (Medical Research Council 1955) In a later study 
a PAS dosage of 15 g daily given daily in either one or two doses to retreatment 
pulmonary TB patients together with streptomycin. After 6 months treatment the 
proportion of patients who were culture negative was similar in the two groups. (East 
African/British Medical Research Council 1968) Nevertheless it should be noted that 
several studies found that once daily dosing of PAS resulted in less intolerance than 
dosing several times daily. (Bridge and Carr 1958, Riska and Tennberg 1962, Lehman 
1969)  
From the perspective of efficacy an experiment in guinea pigs found that a single daily 
dose of PAS was as effective therapeutically as the same dosage given in several daily 
doses; furthermore a single daily dosage of 200 mg was as effective as two 100 mg 
dosages daily. (Karlson and Carr 1958) PAS in a single dosage of 15 g in a small group 
of 4 patients had the second highest early bactericidal activity during the first two days 
of monotherapy and this was exceeded only by that of isoniazid. (Jindani et al 1980) 
When a dosage of 10-12 mg/kg PAS in divided doses accompanied by isoniazid was 
compared to the effects of a dosage of 5-6 mg/kg also in divided doses and 
accompanied by isoniazid in 231 and 233 adult patients respectively culture negativity 
after 16 weeks was 85% and 68% respectively, implying a better result with higher PAS 
concentrations. (Bowerman 1957) 
Despite this long experience with PAS, there is very little published information 
regarding its PK in children. In one of the few reports in English, Sõderjelm (1949) 
described PAS serum concentrations in four children with TBM and spinal TB. PAS was 
given five times daily at four hourly intervals to a total dosage of 300 mg/kg daily. The 
results are presented as figures and the maximum concentrations following dosages of 
50-60 mg/kg are between 5-10 µg/ml. The levels rose rapidly after oral dosing reaching 
a maximum after about 60 minutes; Cmax was followed by a sharp decline. The author 
comments “The total dosage of 300 mg/kg body weight per day given in 5 doses or 
every 4 hours during the daytime appears to establish adequate bacteriostatic serum 
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levels except during the early morning hours because of the omission of the night dose.” 
(Sõderjelm 1949) In an Italian publication the authors Maggioni and Assensio studied 
the concentrations of PAS, both free and combined, in blood urine and cerebrospinal 
fluid (CSF), after oral, intravenous and rectal administration. Their aim was to sustain a 
PAS concentration above 1 mg/100 ml. In the English summary they state “In order to 
achieve constantly a blood level above 1 mg, a total daily dose of 0.3-0.4 g for every kg 
administered every 4 hrs is considered necessary.” They also determined CSF 
concentrations that were 0.5-20% of the blood concentrations, but if the blood/brain 
barrier was normal the entry of PAS into the CSF was poor. Rectal administration of 
PAS was not advised. (Maggioni and Assensio 1950) 
The clinical PK assessment study 
This initial clinical part of this project was designed to study the PK of terizidone and 
PAS in children. However, due to various analytical problems it was not feasible to 
perform the terizidone part of the study. Terizidone basically consists of two molecules 
of cycloserine, which is known for its instability in aqueous solution. During the 
analytical method development (HPLC methods), chemical instability was experienced, 
possibly due to hydrolysis of isoxazolidine ring. After several attempts of method 
development, including the use of different buffers and freezing of the samples, the 
instability of the drug was confirmed in this matrix. It was therefore decided to focus on 
the clinical PK of PAS in children alone.  
The objectives of this study were to evaluate the PK of PAS in children; the group of 
adult patients was included as reference population to allow a direct comparison 
between both groups. The primary questions posed were; (i) do children experience a 
similar PK profile in comparison to adults; (ii) will the PK profile differ when the dose is 
administered in two different regimens; (iii) will the PK profile differ in HIV positive and 
negative patients? 
There were three issues responsible for promoting these questions. First, drug dosing 
regimen in children ideally should be based on pediatric PK data. Unfortunately, a well 
defined PK profile in children is often not available for many drugs, and therefore their 
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relative safety and efficacy have been questioned. The second issue is that currently 
PAS is given twice daily without sufficient PK evidence for the appropriateness of this 
dosing regimen in the pediatric population. It was therefore considered necessary to 
assess if dosing frequency can be reduced. Administration of a single 150 mg/kg dose 
would simplify drug administration and may therefore be desired for children. Third, it is 
necessary to determine if concomitant medications and disease states i.e. HIV and ARV 
may have an impact on the disposition of PAS. 
At the time of its inception, PAS was employed as a first-line anti-TB drug. It was 
introduced into anti-TB chemotherapy during an era when the benefits of combination 
drug therapy had recently been acknowledged but the number of drugs available was 
quite limited. As additional anti-TB drugs with increased activity and better tolerance 
became available, the usage of PAS decreased markedly. Much of our knowledge of 
PAS activity and toxicity today is consequently derived from published experience 
accrued during its use in the 1950s. Today PAS is utilized as an alternative drug for the 
management of drug-resistant TB or for patients with intolerance to other drugs (Wilson 
et al 2003).  
Because PAS is bacteriostatic and because it lacks a post-antibiotic effect, it may be 
desirable to maintain plasma concentrations above the typical MIC for MTB of 1 µg/ml 
throughout the dosing interval. This may be true particularly when the companion drugs 
are weak, such as ethionamide and cycloserine. It was demonstrated that twice-daily 
dosing with this PAS formulation at standard 4 g doses in adults maintained steady 
plasma concentrations above the typical MIC for MTB of 1 µg/ml throughout the dosing 
interval. The success of PAS and other drugs in the management of MDR-TB, defined 
as resistance to at least isoniazid and rifampicin depends upon therapeutic, non-toxic 
drug plasma concentrations reaching the tubercle bacilli. (Peloquin et al 1999) 
In this study, all patients had either MDR-TB or XDR-TB and were receiving a PAS 
containing regimen. Initially blood sampling for up to six hours after drug administration 
was planned. However, since plasma concentrations were still rather high after six 
hours, this sampling schedule was later changed and extended to twelve hours. This 
unique population allowed characterizing and comparing the PK profile between 
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children and adults, two different dose regimens, concomitant medications and the 
effect of HIV infection. No such direct comparison of PK profiles in these divergent 
populations has been performed previously. The approach taken in this study was to 
provide this critical PK information for the second-line anti-TB drug PAS. The results of 
this study provide the descriptive PK and several answers to the basic questions posed. 
Individual PK profile 
The PK profiles for the individual patients i.e. Cmax, Tmax, AUC and Cl/F indicated that 
there was a considerable intra- and inter-patient variability as shown in figures 3 and 4 
above. These discrepancies could not be readily been accounted for but could have 
been attributed to the genetic polymorphism and/or since multiple medications were 
administered to these patients, it is difficult to incriminate PAS or the reseacher as the 
causal agent for the baseline variability observed.  
These patients were on anti-TB regimens that consist of not less than 4 drugs, some of 
the patients were HIV positive as well they were on ARV regimens. Moreover, two 
patients (one child and one adult) had epilepsy and were also taking sodium valproate 
and haloperidol respectively. 
Comparisons between groups 
A comparison between pediatric patients population with the consecutive visits indicated 
that the mean plasma concentration for PAS was reasonably higher in the second visit 
where the patients (children) received 150 mg/kg dose once daily as expected 
compared to the first visit where patient (children) received a dose of 75 mg/kg twice 
daily. The comparisons between the visits in adult group showed the discrepancy 
despite the same dosage of 4 g for each visit. This could explain the inter- and intra- 
individual variability.  
The comparison between children and adults indicated that adults achieved higher 
plasma concentration than children when children received 75 mg/kg dose. It should be 
noted that adults had lower plasma concentrations when compared to children on the 
second visit.  
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The comparison between patients who were HIV positive and those who were HIV 
negative showed no significant difference in the PK parameters between HIV positive 
and HIV negative patients (both adults and children).  
Influence of dosage on plasma profiles 
A review of the dosages revealed that that children were receiving much precise body 
weight adjusted doses as their dosages were calculated on basis of their respective 
exact body weights (75 mg/kg twice daily on the first visit versus 150 mg/kg once daily), 
while adults received a standard dose of 4 g twice daily.  Since the individual body 
weight in adults varied considerably, patients with 50 kg, 60 kg and 70 kg body weight 
will actually receive a PAS dose of 80 mg/kg, 66.67 mg/kg and 57 mg/kg respectively. 
This may explain partially plasma concentrations in adults were sometimes lower than 
in children.  
Plasma profiles before and after dosing 
The plasma levels before and after dosing (trough levels) was recorded for each patient. 
Trough levels were recorded approximately after 12 hours (75 mg/kg) and after 24 
hours (150 mg/kg). The mean trough plasma concentrations were all above the MIC of 
1 µg/ml.  Since the sampling time was up to 12 hours after dosing it was only possible to 
record the values just before dosing for the previous dose and after 12 hours post 
dosing. It was not possible to document the values of 24 hrs post dose on the sampling 
day. Therefore is difficult to conclude whether the once daily dosage (150 mg/kg) will 
maintain the plasma levels above the MIC of 1 µg/ml after a 24 hrs period in children.   
Baseline Values 
As shown in the individual plasma profiles there was a huge inter-individual variation on 
the baseline plasma profiles of both groups of patients e.g. the range for the children 
after a 75 mg/kg dose was 0.90 to 82.7 µg/ml with mean of 28.2 µg/ml. The reasons for 
this variation and a high baseline values can not readily be explained, especially when 
you compare with the variation after a 150 mg/kg dose which was 0 to 51.8 µg/ml. 
However, this may be due to the acetylation status of the patients (slow versus fast) or 
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may be due to the concomitant medications which the patient received, i.e. some 
patients received up to 10 different drugs during the time of this research, the example 
being patient number C4 who was HIV positive and epileptic at the same time. This 
trend was also true in the group of adult patients although in a much lesser extent. 
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7.2 Discussion: In vitro metabolism study 
Simultaneous co-administration of multiple drugs to a patient is highly probable. A 
patient may be co-administered multiple drugs to allow effective treatment of a disease 
(e.g., TB, HIV infection) or for the treatment of multiple diseases or disease symptoms. 
It is now known that drug-drug interactions may have serious, sometimes fatal 
consequences. (Li 2007)  
DDIs remain an important issue in clinical practice and the discovery and development 
of new drugs. Frequently, HLMs, a rich source of human drug-metabolizing enzymes 
such as the cytochrome P450 family, are used as an in vitro assay system. Of the 
human P450 isoenzymes, five have been described to contribute to the metabolism of 
the vast majority of drugs. These are CYP1A2, CYP2C9, CYP2C19, CYP2D6, and 
CYP3A4, albeit some other human P450 enzymes, such as CYP3A5, CYP2B6, and 
CYP2C8, have been gaining increased attention as potentially important drug-
metabolizing enzymes for some drugs. (Obach et al 2006) 
Inhibition of CYP450 enzymes is frequently the underlying mechanism for DDIs. 
(Walsky et al 2004) A significant proportion of drugs undergo metabolism; therefore, the 
issue DDIs mediated by drug metabolizing enzymes is of considerable clinical interest. 
(Kneip et al 2008) 
In vitro systems are utilized to provide answers to fundamental clinical questions 
regarding drug metabolism and drug interactions and to guide the planning and 
interpretation of clinical PK studies. HLMs generally are an important component of 
currently utilized in vitro systems. These preparations contain the various human CYPs 
in proportion to their abundance in human liver in vivo. In vitro models have the 
advantage of lower cost, more rapid implementation, no risk of human drug exposure, 
no need for animal studies, and the availability of greater number of potential chemical 
inhibitors for experimental purposes. In preclinical in vitro studies, tests of the affinity of 
an NCE to CYPs are usually among the first series of assays performed. Inhibition of 
CYP enzymes is frequently the underlying mechanism for DDIs. The understanding of 
this area has led to increased confidence in the use of in vitro data for qualitative 
projection of DDIs in vivo.  
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Although quantitative projections of interactions cannot reliably be made from in vitro 
data, in vitro inhibition data can be used in planning drug interaction studies in humans. 
Positive inhibition findings for a given compound can lead to the conduct of in vivo 
studies to determine the effect of the inhibitory drug on the PK of drugs that are cleared 
by the specific P450 enzyme affected. (Walsky et al 2004) 
In the present study an exploratory in vitro method was utilized which aimed at 
generating baseline data and methodology for the future application of in vitro 
metabolism studies. However, due to the exploratory pilot nature of this part of the 
project, only two CYP isoforms were used to determine the potential for second line 
anti-TB drugs (PAS, ethionamide and terizidone) to inhibit selected important CYP 
enzymes. PAS, ethionamide and terizidone were incubated at various concentrations 
with the marker substrates and known inhibitors. The disappearance of the marker 
substrates was then determined and compared between the inhibitors and test 
compounds. In the present study it has been demonstrated that SLDs (PAS, 
ethionamide and terizidone) did not inhibit the selected isoenzymes in vitro, signifying 
that these compounds are not likely to significantly inhibit drug metabolism mediated by 
CYP2C9 or CYP1A2 isoenzymes. 
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CHAPTER EIGHT 
CONCLUSIONS 
8.1 PK of PAS in children  
Due to the variety of physiologic stages that children pass through during the early 
years of life, it is clear that extrapolation of adult dosimetry will not suffice to describe 
the PK in children. Rather it is important to characterize the PK profiles in children to 
optimize dosing and thereby to improve cure rates and reduce both toxicity and 
emergency of resistance. Optimizing current treatment regimens could provide major 
health benefits and is a necessary prerequisite for appropriate TB treatment.  
Due to the nature of this study and paucity of published PK data for PAS in children, it is 
difficult to compare the current results to the previous data. However, the results 
revealed that a single daily dose of 150 mg/kg PAS administered as the slow release 
PASER formulation can hold certain advantages. With this dosing regimen, single daily 
dosage maximum serum concentrations and AUC0-12 were higher than those after the 
75 mg/kg dosage and to judge by the 12 hr concentrations might be maintained for 
several more hours. Thus it is likely that greater bactericidal activity might be 
engendered, but concentrations above the MIC maintained still for much longer than 12 
hours.  
These data support further clinical study to assess the PK of PAS involving a larger 
patient population to confirm and provide a more robust evidence for the proposed 
optimal PAS dosage regimen in children.  
8.2 In vitro metabolism study  
An in vitro assay for assessment of the enzyme activity of two clinically relevant CYP 
isoenzymes (CYP2C9 or CYP1A2) and inhibition assays were successfully developed 
using an in vitro method in HLMs. The results have shown that PAS, ethionamide and 
terizidone do not inhibit any of these two isoenzymes.  
The results were shown to be relevant, sensitive and reliable, and it is proposed that 
these methods are suitable for this kind of work.  
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APPENDIX I 
Participant information leaflet and consent form for use by parents/legal 
guardians 
Title; Pharmacokinetics and dosing rationale of terizidone and para-aminosalicylic acid 
(PAS) in children and the evaluation of the in vitro metabolism of ethionamide, 
terizidone and PAS. 
Principal Investigator:  Prof Bernd Rosenkranz 
Address: Department of Medicine, Division of Pharmacology, 7th Floor Clinical Building, 
Faculty of Health Sciences, Stellenbosch University, Francie van Zijl Drive, Tygerberg, 
7505 
Contact Numbers: Office phone; +27 21 938 9331 
                                Mobile phone; +27 82 9550017 
  
Your child is being invited to take part in a research project. Please take some time to 
read the information presented here, which will explain the details of this project.  
Please ask the study staff or doctor any questions about any part of this project that you 
do not fully understand. It is very important that you are fully satisfied that you clearly 
understand what this research entails and how your child could be involved. Also, your 
child’s participation is entirely voluntary and you are free to decline to participate.  If 
you say no, this will not affect you or your child negatively in any way whatsoever. You 
are also free to withdraw him/her from the study at any point, even if you do initially 
agree to let him/her take part. 
This study has been approved by the Committee for Human Research at 
Stellenbosch University and will be conducted according to the ethical guidelines and 
principles of the international Declaration of Helsinki, South African Guidelines for Good 
Clinical Practice and the Medical Research Council (MRC) Ethical Guidelines for 
Research. 
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Introduction 
Tuberculosis (TB) is a very important health problem in South Africa and is often 
complicated by resistance to the commonly used medicines. When resistance is present 
other medicines (second-line medicines) must be used. These are not as effective as 
the medicines usually given for tuberculosis and they often have complications.  The 
medicines used to treat drug resistant tuberculosis include para-ethionamide (ETH), 
terizidone /cycloserine (CS) and para-aminosalicylic acid (PAS). All of the second-line 
drugs are not very effective and it is important that they be given in the best possible 
dosage. There is no information regarding the amount of these medicines that get into 
the blood of children. Such information would make it possible for doctors to give much 
more accurate dosages of these medicines than is possible at present. This study aims 
to determine the amount of terizidone and PAS that gets into the blood of children of 
different ages following different doses of terizidone and PAS.   
Before you decide if you want your child to be a part of this study, we want you to know 
about the study. You may choose not to be part of this study. No health care will be 
withheld for your child should you choose not to be part of the study. Your child will still 
receive the standard treatment for drug-resistant tuberculosis used at this hospital.  
This is a consent form. It gives you information about this study. The study staff will talk 
with you about this information. You are free to ask questions about this study at any 
time. If you agree to allow your child to take part in this study, you will be asked to sign 
this consent form. You will get a copy to keep. 
Why is this study being done? 
The purpose of this study is to evaluate the absorption of the antituberculosis 
medicines, terizidone and PAS when given in different doses in children of different 
ages with drug-resistant tuberculosis. To date, the dosage used is based on studies 
done in adults and we do not have reliable data for children. 
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What will happen to my child and what will I have to do if my child is in this 
study? 
If you decide to allow your child to take part in this study a number of investigations will 
be done. The absorption of the medicines will be studied by placing a needle in a vein. 
This needle will then be removed and a soft plastic tube will be left in your child’s arm 
for 8 hours. A small amount of blood will be taken from this tube a total of 5 times in 
eight hours. No further pricking is required during this period. After 8 hours, the plastic 
tube will be removed. The next morning, another single blood sample will be taken. The 
amount of the medicine in the blood will then be measured. All of the above 
investigations (all 6 blood draws in total) will mean taking less than 2 teaspoonfuls (less 
than 10ml) of blood from your child. 
How many children will take part in the study? 
About 30 children will be enrolled in the study. 
How long will your child be in the study? 
The investigations on your child will be completed as soon after being admitted to 
Brooklyn Chest Hospital or Tygerberg Children’s Hospital as is possible and the 
examination of your child by the doctor and the blood investigations should be 
completed within 24 hours. 
Why might the doctor not admit my child / baby to this study? 
The study doctor may decide that your child is too sick to take part in the study.  The 
study might also be cancelled by the site’s Ethics Committee (the committee that 
watches over the safety and rights of research subjects). 
What are the risks of the study? 
Adverse reactions to second-line medicines needed to treat drug-resitant TB medicine 
can occur and your child will be carefully observed for these. Your child/baby’s 
participation in this study will not increase the risk that your child might be affected by 
Stellenbosch University  http://scholar.sun.ac.za/
 94 
 
any of the tuberculosis medicines, but will increase the chance that such reactions will 
be detected early.  
There is a risk of pain and bleeding at the site of insertion of the IV cannula (blood 
drawing needle), but this will soon heal. A gentle application of pressure for a few 
minutes may be required for bleeding after the cannula has been removed.  
Are there benefits to taking part in this study? 
It is likely that your child/baby may derive no benefit from being in this study. Information 
from this study may, however, help experts decide what dosage of terizidone and PAS 
should be recommended for use in other children in future. The study will therefore only 
show benefit at a later stage. 
What other choices does my child/baby have besides this study? 
Should you decide that you do not want your child/baby to take part in this study your 
child’s/baby’s treatment will be unaffected and will continue as usual.  Please talk to 
your doctor about the study if you should be uncertain as to whether your child should 
take part in the study.   
What about confidentiality? 
Every effort will be made to keep your child’s/baby’s personal information confidential, 
however we cannot guarantee absolute confidentiality. Your child’s/baby’s personal 
information may be disclosed if required by law. On our study record we will use codes 
instead of your child’s/baby’s name. Only the study staff will know these codes. The 
study workers will not give out any information about your child/baby without written 
consent from you. Your family’s privacy will be respected. The public health authorities 
will be notified as usual if your child/baby has TB. Any publication of this study will not 
use your child’s/baby’s name or identify your child/baby personally. 
Your child’s/baby’s study records may be inspected by the South African Department of 
Health, study staff or study monitors. The study records will be kept separate from the 
normal medical records. 
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What are the costs to me? 
There is no extra cost to you resulting from your child’s/baby’s participation in the study.   
Will I receive any payment? 
We will re-imburse you transportation money to enable you to attend the hospital should 
you wish to be with your child on the day that the study is undertaken. 
What happens if my child/baby is injured? 
If your child/baby is injured as a result of being in this study, your child/baby will be 
given immediate treatment for his/her injuries at no cost to you. 
 
What are my rights and my child's rights as a research subject? 
Participation in this study is completely voluntary. You may choose not to allow your 
child/baby to take part in this study or take your child/baby out of the study at any time. 
Your child/baby will be treated the same no matter what you decide, there will be no 
penalty. 
We will tell you about new information from this or other studies that may affect your 
child’s/baby’s health, welfare or willingness to stay in this study. 
What do I do if I have questions or problems? 
For questions about this study or a research-related injury, contact: Prof. Bernd 
Rosenkranz with above address or the person who gave you this form. 
You can contact the committee for Human Research at 021-938 9207 if you have any 
concerns or complaints that have not been adequately addressed by your child’s study 
doctor.  
You will receive a copy of this information and consent form for your own records. 
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Declaration by parent/legal guardian 
By signing below, I (name of parent/legal guardian) ……………………………...……. 
agree to allow my child (name of child) ………………………………….… who is ………. 
years old, to take part in a research study entitled: Pharmacokinetics and dosing 
rationale of terizidone and/or PAS in Children. 
 
I declare that: 
• I have read or had read to me this information and consent form and that it is 
written in a language with which I am fluent and comfortable. 
• If my child is older than 7 years, he/she must agree to take part in the study and 
his/her ASSENT must be recorded on this form. 
• I have had a chance to ask questions and all my questions have been adequately 
answered. 
• I understand that taking part in this study is voluntary and I have not been 
pressurised to let my child take part. 
• I may choose to withdraw my child from the study at any time and my child will 
not be penalised or prejudiced in any way. 
• My child may be asked to leave the study before it has finished if the study doctor 
or researcher feels it is in my child’s best interests, or if my child does not follow 
the study plan as agreed to. 
 
 
Signed at (place) ......................…........…………….. on (date) …………....………..  
 
..............................................................  ............................................................  
Signature of parent/legal guardian Signature of witness 
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Declaration by an investigator 
 
I (name) ……………………………………………..……… declare that: 
• I explained the information in this document to …………………………………. 
• I encouraged him/her to ask questions and took adequate time to answer them. 
• I am satisfied that he/she adequately understand all aspects of the research, as 
discussed above 
• I did/did not use an interpreter (if an interpreter is used, then the interpreter must 
sign the declaration below). 
 
Signed at (place) ..............................…………….. On (date) …………....………..  
..............................................................  ................................................ 
Signature of investigator Signature of witness 
 
Declaration by interpreter 
I (name) ……………………………………………..……… declare that: 
• I assisted the investigator (name) ………….…………………………. to explain 
the information in this document to (name of parent/legal guardian) 
……...………………………... using the language medium of Afrikaans/Xhosa. 
• We encouraged him/her to ask questions and took adequate time to answer 
them. 
• I conveyed a factually correct version of what was related to me. 
• I am satisfied that the parent/legal guardian fully understands the content of this 
informed consent document and has had all his/her questions satisfactorily 
answered. 
 
 
Signed at (place) ......................…........……………. On (date) …………....………..  
 
..............................................................  .................................................. 
Signature of interpreter Signature of witness 
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Title; Pharmacokinetics and dosing rationale of terizidone and para-
aminosalicylic acid (PAS) in children and the evaluation of the in vitro metabolism 
of ethionamide, terizidone and PAS. 
We want to ask you to take part in a study about one of the tablets (terizidone or PAS) 
that you are taking as part of your TB treatment. In the study we measure the amount of 
this tablet that goes into your blood and in this way we can see whether we are giving 
too much, too little or just enough of this specific medicine. To do this, we have to draw 
a small amount of blood from you. We will apply some ointment to your arm so that the 
needle prick will be less painful.  
A few minutes later we will use a needle to put a soft plastic tube in your arm. The 
needle will then be taken out and the plastic tube will stay in.  
From this plastic tube we will then take small amounts of blood 5 times in a few hours. 
We only have to prick you once in this time because we can take blood from the soft 
tube without pricking you again. We will then measure the amount of the medicine in 
your blood. The soft plastic tube will be taken out. The next morning we will take one 
more little bit of blood. You can decide if you want to be part the study or not. You do 
not have to take part if you don’t want to. You can decide at any time to stop being a 
part of the study if you are unhappy. 
Assent of minor 
I (Name of Child/Minor)……………………………………………. have been invited to 
take part in the above research project.  
• The study doctor/nurse and my parents have explained the details of the study 
to me and I understand what they have said to me. 
• They have also explained that this study will involve.  
• I also know that I am free to withdraw from the study at any time if I am 
unhappy. 
• By writing my name below, I voluntary agree to take part in this research project.  
I confirm that I have not been forced either by my parents or doctor to take part. 
 
..............................................................  ............................................................  
Name of child Independent witness 
(To be written by the child if possible) 
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Participant information and informed consent form 
Title of research project: Pharmacokinetics and dosing rationale of terizidone and 
para-aminosalicylic acid (PAS) in children and the evaluation of the in vitro metabolism 
of ethionamide, terizidone and PAS. 
Principal Investigator:  Prof Bernd Rosenkranz 
Address: Faculty of Health Sciences, Stellenbosch University, Francie van Zijl Drive, 
Tygerberg, 7505 
Contact Numbers: Tel +27-21-938 9331 (Office); Cellular phone: +27-82-9550017 
You are invited to take part in a research project.  Please take some time to read the 
information presented here, which will explain the details of this project.  Please ask the 
study staff or doctor any questions about any part of this project that you do not fully 
understand.  It is very important that you are fully satisfied that you clearly understand 
what this research entails and how your child could be involved.  Also, your participation 
is entirely voluntary and you are free to decline to participate.  If you say no, this will 
not affect you negatively in any way whatsoever.  You are also free to withdraw from the 
study at any point, even if you do initially agree to take part. 
This study has been approved by the Committee for Human Research at 
Stellenbosch University and will be conducted according to the ethical guidelines and 
principles of the international Declaration of Helsinki, South African Guidelines for Good 
Clinical Practice and the Medical Research Council (MRC) Ethical Guidelines for 
Research. 
Introduction 
Tuberculosis (TB) is a very important health problem in South Africa and is often 
complicated by disseminated forms of TB such as meningitis or widespread lesions 
(miliary) TB, and resistance to the commonly used medicines. PAS, a second-line 
medicine is mostly used in combination with the commonly used drugs for the treatment 
of extensively resistant TB. When resistance is present other medicines (second-line 
medicines) must be used. These are not as effective as the medicines usually given for 
TB and they have more complications than the commonly used (first-line) medicines.  
The medicines used to treat extensively resistant TB almost always include PAS. The 
second-line drugs such as PAS are not as effective as first-line TB drugs and it is 
therefore important that PAS be given in the best possible dosage. The information 
regarding the amount of PAS that gets into the blood is very little. Such information 
would make it possible for doctors to give much more accurate dosages of PAS than is 
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possible at present.  This study aims to determine the amount of PAS that gets into the 
blood of TB patients following the currently recommended and used dose of PAS.   
Before you decide if you want to be a part of this study, we want you to know about the 
study. You may choose not to be part of this study. No health care will be withheld for 
you should you choose not to be part of the study. You will still receive the standard 
treatment for drug-resistant tuberculosis at this hospital.  
This is a consent form. It gives you information about this study.  The study staff will talk 
with you about this information.  You are free to ask questions about this study at any 
time.  If you agree to take part in this study, you will be asked to sign this consent form. 
You will get a copy to keep. 
Why is this study being done? 
The purpose of this study is to evaluate the absorption of the antituberculosis medicine 
PAS when given in the currently recommended dose in patients with drug-resistant TB.  
What will happen to me and what will I have to do if I participate in this study? 
If you decide to take part in this study, a number of investigations will be done. The 
absorption of the medicines will be studied by placing a needle in a vein and taking a 
small amount of blood 6 times soon after the medicines have been given. The amount 
of the medicine in the blood will then be measured. All of the above investigations will 
mean taking less than 2 teaspoonfuls of blood from you at two occasions approximately 
a month apart. 
How many patients will take part in the study? 
About 30 patients will be enrolled in the study. 
How long will you be in the study? 
The investigations will be completed as soon after being admitted to Brooklyn Chest 
Hospital as possible and the examination by the doctor and the blood investigations 
should be completed within a day and will be repeated after a further 1month.  
Why might the doctor not admit me to this study? 
The study doctor may decide that you are too sick to take part in the study.  The study 
might also be cancelled by the site’s Ethics Committee (the committee that watches 
over the safety and rights of research subjects). 
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What are the risks of the study? 
Your participation in this study will not increase the risk that you might be affected by 
PAS, but will increase the chance that such reactions will be detected early. A small 
amount of bleeding may occur at the site where the blood is taken from and this may 
leave a bruise which should soon heal. 
Are there benefits to taking part in this study? 
It is likely that you may derive no benefit from being in this study. Information from this 
study may, however, will help experts decide what dosage of PAS should be 
recommended for use.  
What other choices do I have besides this study? 
Should you decide that you do not want to take part in this study your treatment will be 
unaffected and will continue as usual.  Please talk to your doctor about the study if you 
should be uncertain as to whether you should take part in the study.   
What about confidentiality? 
Every effort will be made to keep your personal information confidential. However we 
cannot guarantee absolute confidentiality. Your personal information may be disclosed if 
required by law. On our study record we will use codes instead of your name. Only the 
study staff will know these codes. The study workers will not give out any information 
about you without written consent from you. Your family’s privacy will be respected. The 
public health authorities will be notified as usual if you have TB. Any publication of this 
study will not use your name or identify you personally. 
Your study records may be inspected by the South African Department of Health, study 
staff or study monitors. The study records will be kept separate from the normal medical 
records. 
What are the costs to me? 
There is no cost to you resulting from participation in the study. All medical care will be 
provided by the study doctor.  
Will I receive any payment? 
We will re-imburse your transportation money to enable you to attend the hospital on 
the day that the study. 
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What happens if I get injured? 
If you get injured as a result of being in this study, you will be given immediate treatment 
for your injuries at no cost to you. 
What are my rights as a research subject? 
Participation in this study is completely voluntary. You may choose not to take part in 
this study or withdraw from the study at any time. You will be treated the same no 
matter what you decide, there will be no penalty. 
We will tell you about new information from this or other studies that may affect your 
health, welfare or willingness to stay in this study.  If you want the results of the study 
inform the study staff. 
What do I do if I have questions or problems? 
For questions about this study or a research-related injury, contact either: 
 
You can contact the Committee for Human Research at 021-938 9207 if you have any 
concerns or complaints that have not been adequately addressed by your child’s study 
doctor. 
You will receive a copy of this information and consent form for your own records. 
 
Declaration by patient 
 
By signing below, I ……………………………...……. agree to take part in a research 
study. 
 
I declare that: 
• I have read or had read to me this information and consent form and that it is 
written in a language with which I am fluent and comfortable. 
• I have had a chance to ask questions and all my questions have been adequately 
answered. 
• I understand that taking part in this study is voluntary and I have not been 
pressurised to take part. 
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• I may choose to withdraw from the study at any time and will not be penalised or 
prejudiced in any way. 
• I may be asked to leave the study before it has finished if the study doctor or 
researcher feels it is in my best interests, or if I do not follow the study plan as 
agreed to. 
 
 
Signed at (place) ......................…........………….. On (date) …………....………..  
 
 
..............................................................               ................................................. 
Signature of a Participant Signature of witness 
 
 
Declaration by investigator 
 
I (name) ……………………………………………..……… declare that: 
 
• I explained the information in this document to ………………………………….. 
• I encouraged him/her to ask questions and took adequate time to answer them. 
• I am satisfied that he/she adequately understand all aspects of the research, as 
discussed above 
• I did/did not use an interpreter (if an interpreter is used, then the interpreter must 
sign the declaration below). 
 
 
Signed at (place) ......................…........……………. On (date) …………………. 
 
 
……………………………                                       ……………………………….. 
 
Signature of investigator Signature of witness 
 
 
 
 
Stellenbosch University  http://scholar.sun.ac.za/
 104 
 
Declaration by interpreter  
 
 
I (name) ……………………………………………..……… declare that: 
 
• I assisted the investigator (name) ………….…………………………. to explain 
the information in this document to (name of parent/legal guardian) 
……...………………………... using the language medium of Afrikaans/Xhosa. 
• We encouraged him/her to ask questions and took adequate time to answer 
them. 
• I conveyed a factually correct version of what was related to me. 
• I am satisfied that the parent/legal guardian fully understands the content of this 
informed consent document and has had all his/her questions satisfactorily 
answered. 
 
 
Signed at (place) ......................…........…………….. On (date) …………....…….. 
 
 
..............................................................  ................................................ 
Signature of interpreter Signature of witness 
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APPENDIX II  
 Research Protocol 
 
 
Clinical Pharmacology of Second-line 
Antituberculosis Drugs. 
RESEARCH PROTOCOL 
 
Investigators: 
 
Anthony Liwa, MD, BSc (Hons) 1 
Bernd Rosenkranz, MD, PhD, FFPM1 
Patrick Bouic, PhD2 
Simon Schaaf, MBChB3 
Peter Donald, MBChB3  
 
Division of Pharmacology (1) 
Synexa Group, South Africa (2) 
Department of Paediatrics (3) 
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Address of correspondence: 
Prof. Bernd Rosenkranz 
Professor and Head 
Division of Pharmacology 
Department of Medicine 
University of Stellenbosch 
PO Box 19063 
Tygerberg, Cape Town, 7505 
South Africa 
Phone: +27-21-938 9331 
Mobile: +27-82-955 0017 
Fax: +27-21-932 6958 
Mail: Rosenkranz@sun.ac.za 
 
[Faculty of Health Sciences, Department of Medicine, Division of 
Pharmacology, PO Box 19063, Tygerberg, 7505, Cape Town, South Africa 
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Preface 
In the current protocol we propose to study: 
1. The in vivo pharmacokinetics (PK) of the second-line antituberculosis 
drugs terizidone and para aminosalycylic acid (PAS) in children  
2. The pharmacokinetics (PK) of the second-line antituberculosis drug para-
aminosalycylic acid (PAS) in adults 
3. The pharmacogenetics of genes relevant for drug elimination such as N-
acetyltransferase among patients treated with PAS for treatment of drug 
resistant tuberculosis. 
4. The in vitro metabolism of the second-line anti tuberculosis drugs 
determination using liver microsomes. 
The primary objective of the protocol is to evaluate the PK profile of terizidone 
and PAS in children by single dose study under strictly managed conditions 
following a defined protocol at set time points after dosing in children and adults. 
In parallel, we plan to assess the pharmacogenetics of PAS, the in vitro 
metabolic stability and the effect of ethionamide, terizidone and PAS on different 
metabolizing enzymes by using standardized methodology. 
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Research protocol 
Title: Pharmacokinetics and dosing rationale of terizidone and para-
aminosalicylic acid (PAS) in children and the evaluation of the in vitro 
metabolism of ethionamide, terizidone and PAS. 
 
Protocol synopsis 
Tuberculosis continues to cause an unacceptably high toll of disease and death 
among children worldwide. Available data has suggested an exponential rise in 
the proportion of the tuberculosis case load caused by children as the incidence 
of tuberculosis rises so that children may constitute nearly 40 per cent of the 
case load in certain high incidence communities. Until now no trials have been 
done in children to establish optimum antituberculosis treatment regimens and 
current treatment guidelines are largely inferred from adult data. This is despite 
the fact that pharmacokinetics in children and especially very young children are 
likely to be different from that in adults. Furthermore resistance to frontline 
therapeutics has resulted in treatment of patients with “second line“ agents that 
are considered more toxic, and the experience of these drugs with children is 
even more limited. Tuberculosis management in children therefore presents 
particularly difficult challenges, and advances in paediatric tuberculosis research 
could provide insights and opportunities for tuberculosis control.  
In the proposed protocol we aim to conduct the pharmacokinetic study of second 
line anti tuberculosis drugs terizidone and PAS in childhood TB across the range 
of dosages and ages in order to determine the validity of the currently suggested 
dose based on adult data. 
We will also conduct the in vitro study of the susceptibility and stability of the 
second line anti TB drugs (ETH, terizidone and PAS) to biotransformation when 
subjected to metabolic enzymes. These drugs will also be incubated with the 
substrates of major enzymes/isoenzymes i.e. cytochrome P450 enzymes 
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(CYPs), flavin containing monooxygenases (FMO) and uridine glucoronosyl 
transferases (UGT) to determine whether they have any effects on these 
enzymes. 
Research hypothesis 
1. Because of developmental changes, the pharmacokinetics of terizidone 
and PAS and resulting serum levels may differ in children of different age 
groups. 
 
2. Young children require a higher body weight adjusted dosage of the 
“second-line” antituberculosis agents, terizidone and PAS than adults to 
achieve equivalent serum concentrations. 
3. Because of the genetic variations of the metabolizing enzymes (N-
acetyltransferase) the serum concentrations may differ in different 
individuals. 
4. The drugs under investigation are metabolically unstable and we therefore 
will investigate the in vitro metabolism and potential for drug-drug 
interactions. 
 
Aim of this study 
1. To document the descriptive pharmacokinetics of the second-line anti-TB   
agents terizidone and PAS in children, in an attempt to provide an insight 
to the dosing rationale of these compounds; these data will be compared 
to the results obtained in adult patients as a reference group. 
2.  To investigate the genetic variation of NAT1and NAT2 in patients with TB 
treated by PAS.  
3. To evaluate the stability and susceptibility to biotransformation of the 
second-line anti-TB drugs (ETH, terizidone and PAS) when subjected to 
metabolic enzymes 
Stellenbosch University  http://scholar.sun.ac.za/
 110 
 
4. To generate baseline data and methodology for the future in vitro 
metabolic analysis of new compounds at the Division of Pharmacology. 
 
Study methodology 
The proposed study is a prospective longitudinal clinical as well as laboratory 
study; We plan to recruit children 13 years or younger and a group of adults 18 
years or older with probable or confirmed drug resistant tuberculosis admitted to 
Brooklyn Hospital for Chest Diseases (BHCD) and In this explorative study, up to 
40 children (for both drugs) and up to 40 adults will be enrolled. 
We plan to measure the serum concentrations at different set points after dosing 
in different age groups. The methodology requires 1 ml of blood for each assay 
and blood will be drawn during each assessment via an indwelling catheter that 
will be inserted on the morning of the evaluation. The indwelling catheter will be 
used to minimize the number of venipunctures required throughout the 
investigation. The serum concentrations will be determined by an established 
high performance liquid chromatography/mass spectrometry method (HPLC-MS). 
Methodology for the in-vitro study will involve the incubation of the test compound 
at concentrations with the enzyme source (Human liver microsomes (HLM)), and 
S9 fractions) with appropriate positive and negative controls. The time spacing 
and replicate number will be according to standardized procedures. The amount 
of parent drug remaining in the incubation media will be analyzed by HPLC/MS 
detection. The current procedure will also involve the incubation of substrates for 
specific isoenzymes with the test compounds using HLM to determine the effects 
of these drugs on different metabolizing enzymes. 
Microsoft excel will be used to capture the data and STATISTICA version 8 
(StatSoft Inc. (2008) STATISTICA (data analysis software system) will be used to 
analyse the data. Summary statistics will be used to describe the variables. 
Distribution of variables will be presented as histograms and or as frequency 
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tables. Medians or means will be used as the measures of central location for 
ordinal and continuous responses and standard deviations and quartiles as 
indicators of spread. 
Time plan 
We have planned to submit the protocol between August-September 2009 and 
have full Ethics approval for the study to start shortly thereafter. The aim is to 
collect data according to the protocol within a year. Data analysis and writing of 
the manuscript could be completed in 2 months. It would be possible to aim at 
the final manuscript at the end of year 2010 for the final master’s thesis 
presentation and graduation. At the time of the submission of this amendment, 
the clinical project is ongoing (paediatric population).  
The in vitro study will have a specific timeline, its implementation will commence 
after the approval from the ethical committee and the arrival of the required study 
materials. At the time of submission of this amendment, the laboratory work is 
being initiated.  
Conclusion 
The data generated in this study will be used as guidance for future studies 
involving much larger populations. We plan to present the data at congresses 
and to write this up for publications. 
Funding and budget 
Partial funding from the departmental funds is readily available. In addition, 
funding is available from NRF grants provided to Prof. P. Donald.  
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Introduction 
Tuberculosis continues to cause an unacceptably high toll of disease and death 
among children worldwide. (Newton et al., 2008) Approximately 8.3million new 
TB cases were diagnosed globally in 2000. It is estimated that 884,019 (11%) 
cases occurred among children, with the highest burden noted in areas of 
endemicity. A survey conducted in Cape Town, South Africa, indicated that 13% 
of cases entered into the register were found among children < 13 years of age. 
(Marais et al., 2004) Children are particularly vulnerable to severe disease and 
death following infection. Few trials have been done in children to establish 
optimum antituberculosis treatment regimens and current treatment guidelines 
are largely inferred from adult data. (Newton et al., 2008) Resistance to frontline 
therapeutics, most notably, isoniazid (INH) and rifampicin, results in treatment of 
patients with “second-line” agents that are less effective and/or more toxic. 
Among the second tier drugs for the treatment of multidrug-resistant tuberculosis, 
ethionamide (ETH), (Vanneli et al., 2002) and terizidone or cycloserine (CS) are 
generally used first because of efficacy, side effect profile, and historical use in 
tuberculosis (Murkherjee et al., 2004). Dosages for children are based on weight 
and extrapolated from data from studies with adults, yet pharmacokinetics for 
children, especially very young children, is likely to be different than for adults. 
Studies of ethambutol and pyrazinamide have found lower plasma drug levels 
and shorter half-lives in children than in adults using the same dosages. 
(Graham et al., 2006) Similar conclusions were drawn from a study of isoniazid 
pharmacokinetics in South African children. (Schaaf et al., 2005) 
In the light of the above remarks we conclude that tuberculosis management in 
children presents particularly difficult challenges, and that advances in paediatric 
tuberculosis research could provide wider insights and opportunities for 
tuberculosis control.  
In the proposed protocol we aim to study the pharmacokinetics of second-line 
anti tuberculosis drugs terizidone and PAS in childhood TB across the range of 
dosages and ages in order to determine the validity of the currently suggested 
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doses based on adult target concentrations as well as pharmacokinetic data 
obtained in a reference group of adult patients in the present study. 
We also aim to conduct the in vitro evaluation of susceptibility and stability of the 
second line anti TB drugs (ETH, terizidone and PAS) to biotransformation when 
subjected to metabolic enzymes. These drugs will also be incubated with the 
substrates of major enzymes/isoenzymes i.e. cytochrome P450 enzymes 
(CYPs), flavin containing monooxygenases (FMO) and uridine glucoronosyl 
transferases to determine whether they have any inhibitory effects on these 
enzymes. 
Background information and literature review 
Burden of TB 
Tuberculosis (TB) is a highly contagious chronic granulomatous bacterial 
infection, and is still a leading killer worldwide. TB has returned with a new face 
and the global scourge of multi-drug resistant TB (MDR TB) is reaching epidemic 
proportions. Rates of HIV infection among TB patients are correspondingly high, 
exceeding 60% in South Africa, Botswana, Zambia, and Zimbabwe. (Du Toit et 
al., 2006) It is estimated that one third of the world’s population is infected with 
mycobacterium tuberculosis, and that each year, about 9 million people develop 
TB, of whom about 2 million die. Of the 9 million annual TB cases, about 1 million 
(11%) occur in children. Of these childhood cases, 75% occur annually in 22 high 
burden countries. (WHO Guidelines., 2006) TB in the Western Cape Province 
was 520/100,000 in 1998 and 678/100,000 in 2003. (Cape Town TB Control 
Progress report 1997-2003) 
Tuberculosis in children 
Children are mainly infected by adult pulmonary TB source cases and childhood 
TB therefore reflects the intensity of ongoing transmission of Mycobacterium 
tuberculosis within a community. (Schaaf et al., 2005) Since most children 
acquire the organisms from adults in their surroundings, the epidemiology of 
childhood tuberculosis follows that in adults. Tuberculosis case load represented 
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by children suggest an exponential rise in the proportion of the tuberculosis case 
load caused by children as the tuberculosis rises, nearly 40 per cent of the case 
load in certain high incidence communities. (Donald PR., 2002) In Cape Town, 
South Africa, childrensuffer considerable morbidity: 207/439 (47.1%) had disease 
manifestations other than uncomplicated lymph node disease, while 26/439 
(5.9%) were diagnosed with disseminated (miliary) disease and/or tuberculous 
meningitis (TBM). (Marais et al., 2004) 
Pediatric pharmacology: Consequences of immaturity 
Developmental changes are responsible for differences in drug disposition seen 
throughout childhood, therefore the weight-adjusted drug dose may not be the 
same for different age groups. During a period of latent or rapid growth, some 
drugs that may cause severe or protracted toxicity can alter the final mature 
expression of a system.. These concepts of drug effects on host effect on drug 
need to be appreciated for appropriate use of drugs in children. (Pradhan et al., 
1986) Age-related differences in PK, in addition to those of body size, can be 
used to guide calculations. Altered absorption, distribution, and elimination are 
most marked in the newborn, but for many drugs, disposition process may equal 
or exceed the adult capacity by late infancy and /or childhood. (Pradhan et al., 
1986) 
 
Drug-resistant Tuberculosis 
The treatment and control of TB is more complex when the organism is resistant 
to the action of antituberculosis drugs. MDR-TB are associated with mortality as 
high as 43–93% in adults, despite limited information in children,  resistance 
patterns in children have generally been found to be similar to those of adults 
from the same areas and similar backgrounds. (Nelson et al., 2004) 
Traditionally, patients with drug-resistant tuberculosis are classified as having 
acquired or primary drug resistance on the basis of a history of previous 
treatment. In the survey in 35 countries, the median prevalence of primary 
resistance to any antituberculous drug was 9·9% (range 2-41) and that of 
acquired resistance was 36%. (Van Rie et al,. 2000). In a study conducted at 
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Tygerberg Children Hospital (TCH). Among 313 children (range 2 weeks -/12.9 
years) in whom drug susceptibility test (DST) results were available, 40 (12.8%) 
and 17 (5.4%) were infected with strains resistant to isoniazid and rifampicin, 
respectively. All who had rifampicin-resistant strains had co-existent resistance to 
isoniazid (MDR TB). Only 1/40 (2.5%) children with resistance to isoniazid and/or 
rifampicin was also resistant to ethambutol. (Schaaf et al., 2007) 
Extensively drug resistant tuberculosis has now been reported from 45 countries, 
though this almost certainly underestimates its true extent as many countries lack 
laboratory facilities to detect resistance to second line drugs. The outbreak in 
South Africa was particularly alarming because, most patients with extensively 
drug resistant tuberculosis had no history of tuberculosis treatment, implying 
person to person transmission of extensively drug resistant tuberculosis, and 
because of evidence of transmission in healthcare settings. (Grant et al., 2008)  
Second-line anti-TB drugs 
Terizidone 
Terizidone (a derivative of cycloserine) It has a bacteriostatic effect at the usual 
dose, is used in combination with other second-line agents in the treatment of 
MDR-TB, as it does not share cross resistance with other anti TB drugs.  It is 
believed to have lower incidence of side effects than cycloserine. (WHO, 
Geneva., 2002. SAMF 8th Ed, 2008) 
 
Para-aminosalicylic acid (PAS) 
PAS is bacteriostatic drug, in-vitro, most strains of the mycobacterium 
tuberculosis are sensitive to a concentration of 1µg/ml. It is administered orally in 
a daily dose of 10 to 12g. (Goodman and Gilman., 2006) PAS is used primarily 
as a second-line drug to treat MDR TB. (Mathys et al., 2009) 
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Hypothesis 
4. Because of developmental changes, the pharmacokinetics of terizidone 
and PAS and resulting serum levels may differ in children of different age 
groups. 
5. Young children require a higher body weight adjusted dosage of the 
“second-line” antituberculosis agents, terizidone and PAS than adults to 
achieve equivalent serum concentrations. 
6. Because of the genetic variations of the metabolizing enzyme (N-
acetyltransferase) the serum concentrations may differ in different 
individuals. 
7. The drugs under investigation are metabolically unstable and have a 
potential for drug-drug interactions.  
 
 
Rationale 
Children in endemic settings are highly susceptible to TB infection and disease. 
Because of the rising rates of MDR-TB and because children are at a higher risk 
of developing disseminated forms of tuberculosis, information on drug dosing for 
second line drugs in this patient population is urgently needed. 
 
Aims of study 
1. To document the descriptive pharmacokinetics of the second-line 
antituberculosis agents terizidone and PAS in children, in an attempt to 
provide an insight to the dosing rationale of these compounds; these data 
will be compared to the results obtained in adult patients as a reference 
group. 
2. Investigate the genetic variation of NAT1and NAT2 in patients with 
tuberculosis treated by PAS. 
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3. To evaluate the susceptibility and stability of the second line anti TB drugs 
(ETH, terizidone and PAS) to biotransformation when subjected to 
metabolic enzymes. 
4. To generate baseline data and methodology for the future applicationif in-
vitro metabolism studies at the Division of Pharmacology. 
 
Study methodology 
Study design 
3. A prospective, longitudinal, hospital based clinical pharmacokinetic study.  
4. An in-vitro laboratory based analytical study 
 
Study setting and study population 
The study recruitment sites will be Tygerberg Children's Hospital (TCH) and 
Brooklyn Chest Hospital (BCH) both associated with the Stellenbosch University 
and situated in the district of Cape Town. TCH is a tertiary level hospital and 
serves as referral hospital for complicated TB cases from the surrounding high-
burden communities.  
BHC is a specialized TB hospital, focusing on the long-term treatment of 
complicated and drug-resistant TB. 
Subjects and sites 
Children with probable or confirmed drug-resistant tuberculosis admitted to the 
above mentioned hospitals, which are on treatment with terizidone and/or PAS.  
Sample size considerations  
In this explorative study a valid estimation of number of cases needed for 
statistical significance cannot be made as there is neither data on terizidone, 
PAS serum levels nor on standard deviations in children of different age groups. 
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For reasons of practicability and according to the incidence of a therapy regimen 
containing terizidone and PAS in childhood tuberculosis, we plan to enrole up to 
30 children for terizidone, up to 10 children for PAS and up to 40 adults for PAS, 
however this relatively small sample size may have less statistical power. 
Inclusion criteria  
Children between 2 month and 13 years of age and adults older than 18 years 
who require treatment with second line anti-TB drugs terizidone and PAS and are 
admitted to one of the participating hospitals, who are medically stable and 
accompanied by a parent or legal guardian who has given written, informed 
consent for the participation of the child in the study. Patients included in another 
study (Schaaf et al) involving PK of ethionamide may also be included in the 
present protocol 
Exclusion criteria  
Children who are medically unstable such as those with severe anaemia, severe 
malnutrition, diarrhea and dehydration or other medical condition such as to 
make the drawing of blood inadvisable, or whose parents or legal guardian are 
unwilling to give permission for their children to participate in the study.  
Procedure for in-vivo study 
The serum concentration of terizidone will be determined at time 0, -1, -2, -3, -4-, 
-6, -  and 24 hours hours after dosing in groups of up to 10 children from each 
age group, in children 3 months -<2 years, 2-<6 years, and 6-12 years of age 
receiving the currently recomended dosage. This methodology requires 1 ml of 
blood for each assay and a total of 7 ml of blood will thus be drawn during 
each assessment. 
The serum concentrations of PAS will be determined at time 0, - 2, - 4, - 6, - 8, - 
and 12 or 24 hours in one group of up to 10 children aged between 3 months 
and 13 years after receiving a single dose per day. In adults, blood sampling 
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times will be 0, -2, -3, -4, -5, -6, -8 and 12 or 24 hours. Blood sampling will be 
repeated after 2 to 4 weeks after receiving a multiple dose per day (twice daily). 
The dose will be kept refrigerated and will be given with an orange juice under 
observation from the researcher. This methodology requires 1 ml of blood for 
each assay and a total of 12 ml of blood will thus be drawn for both 
assessments in children and a total of 20 ml in adults.  
These amounts does not exceed the allowable sample volume of 9.6, 36, 96 ml 
for the full term neonates, children (3 years) and children (12 years), respectively 
(Abdel-Rahman et al., 2007). However, considerations will be given to patients 
with diarrhea, severe anaemia, severe malnutrition or any other medical 
conditions that restrict blood sampling. 
In the paediatric population, an anesthetic patch will be applied for 45 minutes 
before inserting an indwelling catheter that will be used so that venipunctures are 
reduced throughout the investigation. 
Serum concentrations will be determined by an established high performance 
liquid chromatography with mass spectrometry (HPLC-MS) methodology. 
Procedure for in-vitro metabolism  
The test compound will be incubated at concentrations with the enzyme source 
(Human liver microsomes (HLMs), and/or S9 fractions) with appropriate positive 
and negative controls. At varying time intervals, the reactions will be terminated. 
The time spacing and replicate number will be according to the standardized 
procedures. The amount of parent drug remaining in the incubation media will be 
analyzed by HPLC-MS.  
The current procedure will involve the incubation of substrates for specific 
isoenzymes with the test compounds and the enzyme source (Human liver 
microsomes) to determine the effects of these drugs to different metabolizing 
enzymes. 
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Procedure for pharmacogenetics assays 
The blood cell pellet obtained from blood samples taken for pharmacokinetic 
assays will be stored frozen at -40oC or below. In an initial stage it is planned to 
determine the genotype for both types of N-acetyl-transferase (NAT-1 and NAT-
2). Samples may also be analysed for other proteins involved in drug elimination 
(such as P-glycoprotein) at a later stage.  
 
Data management and statistical analysis  
Microsoft Excel will be used to capture the data and STATISTICA version 8 
(StatSoft Inc. (2008) STATISTICA (data analysis software systems. will be used 
to analyse the data. Data will be collected on case report forms (CRF) and study 
flowcharts and then entered into an Access or SPSS database.  
Summary statistics will be used to describe the variables. Distribution of variables 
will be presented as histograms and or as frequency tables. Medians or means 
will be used as the measures of central location for ordinal and continuous 
responses and standard deviations and quartiles as indicators of spread. The 
relationship between continuous response variables and nominal input variables 
will be analysed using appropriate analysis of variance (ANOVA). When ordinal 
response variables are compared versus a nominal input variable, non-
parametric ANOVA methods will be used. For completely randomized designs 
the Mann-Whitney test or the Kruskal-Wallis test will be used and for repeated 
measures the Wilcoxon- or Friedman tests will be used. 
A population pharmacokinetic analysis will also be conducted to determine the 
pharmacokinetic effects of different covariates and to quantify the covariates 
contributing to the studied drugs’ clearance and volume of distribution population 
parameters including variability in order to establish an initial estimate of the 
major covariates required for dosing predictions.  
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Ethical consideration  
The study will be conducted according to the principles of Good Clinical Practice, 
South African and internationally accepted ethical standards taking into account 
the Declaration of Helsinki and International Conference on Harmonisation (ICH) 
guidelines. 
All patients referred to the hospital for treatment might participate if they are 
eligible and a written informed consent (for children: by parents or legal 
guardians) is given. Before enrolment, children older than 7 years will be asked 
to assent after being fully informed about the rationale, procedure, data 
management as well as potential benefits and risks of the study.  
The patients participating in the study will not directly benefit from the study; 
however, the study will provide important information for the optimal treatment 
and the use of terizidone and PAS in childhood tuberculosis. 
This study is in the interest of improving medical care for children with 
tuberculosis in need of the second line drugs, terizidone and PAS. No alteration 
in the prescribed treatment of the children will be made other than that prescribed 
by the attending physicians. 
The consent form will be available in English, Afrikaans and isiXhosa, the parents 
will be informed of the possibility to revoke informed consent even though it was 
made in writing. There will be no financial incentive offered for study participation. 
Blood samples for measurements of serum levels and additional parameters will 
be collected through a permanent angiocatheter that will be inserted at the 
beginning of each study day to minimize the number of necessary venipunctures. 
Obtained data will be collected in a database using a unique anonymous subject 
code for each patient. Identified information linked to the study code will be 
recorded separately. The confidentiality of all information of a personal nature will 
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be maintained and ensured at all times. Only the researcher and authorized 
officials affiliated to control bodies will be allowed access to personal information. 
It is the intention of the researcher to present and publish the findings of the 
study in an appropriate medical journal without, as indicated, divulging any 
information of a personal nature. 
Risks associated with participation in the study 
The participants will be treated as usual by their attending physician. The 
investigators will not in any way alter their drug therapy. The risks are therefore 
those associated with venipuncture. These include pain, bruising and bleeding at 
the site of IV cannula insertion.  
To minimize these risks, an indwelling IV cannula will be inserted so that repeat 
venipuncture is minimized and a topical anaesthetic gel will be used. These 
symptoms usually resolve spontaneously or may require the application of gentle 
pressure to the area for a few minutes after cannula removal.   
A further risk is the drawing of blood in children who are anaemic or dehydrated. 
To prevent this, children who are medically unstable such as those with severe 
anaemia, severe malnutrition, diarrhea and dehydration or other medical 
condition such as to make the drawing of blood inadvisable will be excluded from 
the study.   
Furthermore, the amount of blood drawn will be limited to 8ml in total, which is 
less than the upper limit recommended in guidelines (Abdel-Rahman et al., 
2007).  
Feasibility of the study  
The participating hospitals admit good number of children per year 
(approximately 120-130) of whom great majority have either drug-resistant 
tuberculosis and require second line anti tuberculosis agents. It should therefore 
be possible to enroll the proposed number of patients at these facilities within a 
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time a year. Furthermore, the Division of Pharmacology has a long standing and 
extensive experience in conducting pharmacokinetic studies in childhood 
tuberculosis. It has previously been involved in studies which characterized the 
pharmacokinetic disposition of isoniazid in children and has produced refined the 
methodology for determining the serum concentrations of several 
antituberculosis agents. 
For the in vitro study we are collaborating with experts from Synexa group, South 
Africa, who have considerable experience in such kind of laboratory work; the 
reagents for the in vitro study are readily available commercially. 
 
Conclusion 
The data generated in this study will be used as guidance for future studies 
involving much larger populations. We plan to present the data at congresses 
and to write this up for publications. 
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Time plan 
We have planned to submit the protocol between August-September 2009 and 
have full Ethics approval for the study to start shortly thereafter. The aim is to 
collect data according to the protocol within a year. Data entry analysis and 
writing of the manuscript could be completed in 2 months. It would be possible to 
aim at the final manuscript at the end of year 2010 for the final master’s thesis 
presentation. At the time of the submission of this amendment, the clinical project 
is ongoing (paediatric population).  
The in vitro study will have a specific timeline, its implementation will commence 
after the approval from the ethical committee and the arrival of the required study 
materials. 
Funding and budget: 
Partial funding from the departmental funds is readily available. In addition, 
funding requests/ applications have been submitted to Medical Research Council 
and Harry Crossley Foundation and we await for feedback and possible 
approval. The budget summary is as indicated in the table below: 
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Table 1: Budget 
 
 Unit cost 
(R) 
No. of 
units 
Sub-total 
(R) 
Consumables    
 Blood collection and specimens     75  180 13 500  
 Micro centrifuge polypyrolene tubes   950      1     950  
Reagents    
Liver microsomes 1660    25 41 500  
S9 fractions   650   20 13 000  
Co-factors (NADPH, UDPGA)     9 000  
Other reagents (DMSO, Phosphate 
buffer, Methanol, Acetonitrile) 
    4 000  
 
Substrates    20 000 
Laboratory analyses    
 Development and Validation of assays    10 000  
 Analysis of specimens   800  180 144 000  
Travel    
 Parents/ caregivers to and from the 
hospital 
  100   30   3 000  
 Cost for courier services - -   8 000 
Total 266 950 
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Appendix 
Terms and definitions relating to tuberculosis and drug resistance  
• Drug resistant tuberculosis -Tuberculosis that is resistant to any first line 
antituberculosis drug  
• Multidrug resistant tuberculosis (MDR-TB) -Tuberculosis that is 
resistant to at least isoniazid and rifampicin 
• Extensively drug resistant tuberculosis (XDR-TB)-Tuberculosis that is 
resistant to at least isoniazid and rifampicin and also to a fluoroquinolone 
and a second line injectable agent (amikacin, capreomycin, or kanamycin) 
• Drug resistance in new tuberculosis cases (primary drug resistance)-
Drug resistant tuberculosis in a person with no history of tuberculosis 
treatment, implying they were infected with a resistant organism. This 
reflects person to person transmission of drug resistant tuberculosis 
• Drug resistance among previously treated cases ("acquired" drug 
resistance)-Drug resistant tuberculosis in a person with a history of 
tuberculosis treatment. This reflects drug resistance acquired during 
tuberculosis treatment but may also reflect infection or reinfection with a 
resistant organism (Grant et al., 2008)  
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The standardized regimen for treatment of multidrug-resistant TB in South Africa 
is as shown in the table below: 
Standardized Regimen for Treatment of Multidrug-Resistant TB (MDR-TB) 
in SA 
Treatment should be started in a referral centre and be adjusted according 
to a patient weight 
Intensive phase: 4 months 
Doses given daily 
Pre-
treatment 
body 
weight Kanamycin Ethionamide   PZA Ofloxacin   Ethambutol 
or terizidone 
< 50 kg 
   50-65 
≥ 65 
750 mg 
1000 mg 
1000 mg 
500 mg 
750 mg 
750 mg 
1000 
mg 
1500 
mg 
2000 
mg 
600 mg 
600 mg 
800 mg 
800mg 
1200mg 
1200 mg 
750 
mg 
750 
mg 
750 
mg 
Continuation phase 12-18 months depending on culture 
conversion 
Doses give daily 
 Pre-
treatment 
body 
weight 
       Ethionamide          Ofloxacin Ethambutol or 
terizidone 
< 50 kg 
   50-65 kg 
≥ 65 kg 
500 mg 
750 mg 
750 mg 
60 mg 
600 mg 
800 mg 
800 mg 
1200 mg 
1200 mg 
500 
mg 
750 
mg 
750 
mg 
Ethambutol is used if strain still susceptible. Terizidone is used if strain resistant 
to ethambutol. Reduce terizidone dose to 500 mg if weight ≤ 35 kg. Pyridoxine 
(Vit B6) 150 mg to be given to patients on terizidone. Some provinces may be 
using cycloserine instead of terizidone. (Begley, 2007)  
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STELLENBOSCH UNIVERSITY 
Participant information leaflet and consent form for use by 
parents/legal guardians 
Title; Pharmacokinetics and dosing rationale of terizidone and para-
aminosalicylic acid (PAS) in children and the evaluation of the in vitro 
metabolism of ethionamide, terizidone and PAS. 
Reference number: 
Principal Investigator:  Prof Bernd Rosenkranz 
Address: Department of Medicine, Division of Pharmacology, 7th Floor Clinical 
Building, Faculty of Health Sciences, Stellenbosch University, Francie van Zijl 
Drive, Tygerberg, 7505 
Contact Numbers: Office phone; +27 21 938 9331 
                                Mobile phone; +27-82-9550017 
  
Your child is being invited to take part in a research project. Please take some 
time to read the information presented here, which will explain the details of this 
project.  Please ask the study staff or doctor any questions about any part of this 
project that you do not fully understand. It is very important that you are fully 
satisfied that you clearly understand what this research entails and how your 
child could be involved. Also, your child’s participation is entirely voluntary and 
you are free to decline to participate.  If you say no, this will not affect you or your 
child negatively in any way whatsoever. You are also free to withdraw him/her 
from the study at any point, even if you do initially agree to let him/her take part. 
This study has been approved by the Committee for Human Research at 
Stellenbosch University and will be conducted according to the ethical 
guidelines and principles of the international Declaration of Helsinki, South 
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African Guidelines for Good Clinical Practice and the Medical Research Council 
(MRC) Ethical Guidelines for Research. 
Introduction 
Tuberculosis (TB) is a very important health problem in South Africa and is often 
complicated by resistance to the commonly used medicines. When resistance is 
present other medicines (second-line medicines) must be used. These are not as 
effective as the medicines usually given for tuberculosis and they often have 
complications.  The medicines used to treat drug resistant tuberculosis include 
para-ethionamide (ETH), terizidone /cycloserine (CS) and para-aminosalicylic 
acid (PAS). All of the second-line drugs are not very effective and it is important 
that they be given in the best possible dosage. There is no information regarding 
the amount of these medicines that get into the blood of children. Such 
information would make it possible for doctors to give much more accurate 
dosages of these medicines than is possible at present. This study aims to 
determine the amount of terizidone and PAS that gets into the blood of children 
of different ages following different doses of terizidone and PAS.   
Before you decide if you want your child to be a part of this study, we want you to 
know about the study. You may choose not to be part of this study. No health 
care will be withheld for your child should you choose not to be part of the study. 
Your child will still receive the standard treatment for drug-resistant tuberculosis 
used at this hospital.  
This is a consent form. It gives you information about this study. The study staff 
will talk with you about this information. You are free to ask questions about this 
study at any time. If you agree to allow your child to take part in this study, you 
will be asked to sign this consent form. You will get a copy to keep. 
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Why is this study being done? 
The purpose of this study is to evaluate the absorption of the antituberculosis 
medicines, terizidone and PAS when given in different doses in children of 
different ages with drug-resistant tuberculosis. To date, the dosage used is 
based on studies done in adults and we do not have reliable data for children. 
What will happen to my child and what will I have to do if my child is in this 
study? 
If you decide to allow your child to take part in this study a number of 
investigations will be done. The absorption of the medicines will be studied by 
placing a needle in a vein. This needle will then be removed and a soft plastic 
tube will be left in your child’s arm for 8 hours. A small amount of blood will be 
taken from this tube a total of 5 times in eight hours. No further pricking is 
required during this period. After 8 hours, the plastic tube will be removed. The 
next morning, another single blood sample will be taken. The amount of the 
medicine in the blood will then be measured. All of the above investigations (all 6 
blood draws in total) will mean taking less than 2 teaspoonfuls (less than 10ml) of 
blood from your child. 
How many children will take part in the study? 
About 30 children will be enrolled in the study. 
How long will your child be in the study? 
The investigations on your child will be completed as soon after being admitted to 
Brooklyn Hospital or Tygerberg Children’s Hospital as is possible and the 
examination of your child by the doctor and the blood investigations should be 
completed within 24 hours. 
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Why might the doctor not admit my child / baby to this study? 
The study doctor may decide that your child is too sick to take part in the study.  
The study might also be cancelled by the site’s Ethics Committee (the committee 
that watches over the safety and rights of research subjects). 
 
What are the risks of the study? 
Adverse reactions to second-line medicines needed to treat drug-resitant TB 
medicine can occur and your child will be carefully observed for these. Your 
child/baby’s participation in this study will not increase the risk that your child 
might be affected by any of the tuberculosis medicines, but will increase the 
chance that such reactions will be detected early.  
There is a risk of pain and bleeding at the site of insertion of the IV cannula 
(blood drawing needle), but this will soon heal. A gentle application of pressure 
for a few minutes may be required for bleeding after the cannula has been 
removed.  
Are there benefits to taking part in this study? 
It is likely that your child/baby may derive no benefit from being in this study. 
Information from this study may, however, help experts decide what dosage of 
Terizidone and PAS should be recommended for use in other children in future. 
The study will therefore only show benefit at a leter stage. 
What other choices does my child/baby have besides this study? 
Should you decide that you do not want your child/baby to take part in this study 
your child’s/baby’s treatment will be unaffected and will continue as usual.  
Please talk to your doctor about the study if you should be uncertain as to 
whether your child should take part in the study.   
What about confidentiality? 
Every effort will be made to keep your child’s/baby’s personal information 
confidential, however we cannot guarantee absolute confidentiality. Your 
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child’s/baby’s personal information may be disclosed if required by law. On our 
study record we will use codes instead of your child’s/baby’s name. Only the 
study staff will know these codes. The study workers will not give out any 
information about your child/baby without written consent from you. Your family’s 
privacy will be respected. The public health authorities will be notified as usual if 
your child/baby has TB. Any publication of this study will not use your 
child’s/baby’s name or identify your child/baby personally. 
Your child’s/baby’s study records may be inspected by the South African 
Department of Health, study staff or study monitors. The study records will be 
kept separate from the normal medical records. 
What are the costs to me? 
There is no extra cost to you resulting from your child’s/baby’s participation in the 
study.   
Will I receive any payment? 
We will re-imburse you transportation money to enable you to attend the hospital 
should you wish to be with your child on the day that the study is undertaken. 
What happens if my child/baby is injured? 
If your child/baby is injured as a result of being in this study, your child/baby will 
be given immediate treatment for his/her injuries at no cost to you. 
 
What are my rights and my child's rights as a research subject? 
Participation in this study is completely voluntary. You may choose not to allow 
your child/baby to take part in this study or take your child/baby out of the study 
at any time. Your child/baby will be treated the same no matter what you decide, 
there will be no penalty. 
We will tell you about new information from this or other studies that may affect 
your child’s/baby’s health, welfare or willingness to stay in this study. 
Stellenbosch University  http://scholar.sun.ac.za/
 136 
 
What do I do if I have questions or problems? 
For questions about this study or a research-related injury, contact: Prof Bernd 
Rosenkranz with above address or the person who gave you this form. 
You can contact the committee for Human Research at 021-938 9207 if you have 
any concerns or complaints that have not been adequately addressed by your 
child’s study doctor. 
You will receive a copy of this information and consent form for your own 
records. 
Declaration by parent/legal guardian 
 
By signing below, I (name of parent/legal guardian) 
……………………………...……. agree to allow my child (name of child) 
………………………………….… who is ………. years old, to take part in a 
research study entitled: Pharmacokinetics and dosing rationale of terizidone 
and/or PAS in Children. 
I declare that: 
 
• I have read or had read to me this information and consent form and that it 
is written in a language with which I am fluent and comfortable. 
• If my child is older than 7 years, he/she must agree to take part in the 
study and his/her ASSENT must be recorded on this form. 
• I have had a chance to ask questions and all my questions have been 
adequately answered. 
• I understand that taking part in this study is voluntary and I have not been 
pressurised to let my child take part. 
• I may choose to withdraw my child from the study at any time and my child 
will not be penalised or prejudiced in any way. 
• My child may be asked to leave the study before it has finished if the study 
doctor or researcher feels it is in my child’s best interests, or if my child 
does not follow the study plan as agreed to. 
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Signed at (place) ......................…........…………….. on (date) …………....………..  
 
............................................................... ............................................... 
Signature of parent/legal guardian Signature of witness 
 
Declaration by investigator 
 
I (name) ……………………………………………..……… declare that: 
 
• I explained the information in this document to 
………………………………….. 
• I encouraged him/her to ask questions and took adequate time to answer 
them. 
• I am satisfied that he/she adequately understand all aspects of the 
research, as discussed above 
• I did/did not use an interpreter (if a interpreter is used, then the interpreter 
must sign the declaration below). 
 
Signed at (place) ...........…........…………….. On (date) …………....………..  
 
............................................................... ........................................ 
Signature of investigator Signature of witness 
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Declaration by interpreter 
 
I (name) ……………………………………………..……… declare that: 
 
• I assisted the investigator (name) ………….…………………………. to 
explain the information in this document to (name of parent/legal 
guardian) ……...………………………... using the language medium of 
Afrikaans/Xhosa. 
• We encouraged him/her to ask questions and took adequate time to 
answer them. 
• I conveyed a factually correct version of what was related to me. 
• I am satisfied that the parent/legal guardian fully understands the content 
of this informed consent document and has had all his/her questions 
satisfactorily answered. 
 
 
Signed at (place) ......................…........…….. On (date)…………....………..  
 
............................................................... ......................................... 
Signature of interpreter Signature of witness 
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Title; Pharmacokinetics and dosing rationale of terizidone and para-
aminosalicylic acid (PAS) in children and the evaluation of the in vitro 
metabolism of ethionamide, terizidone and PAS. 
We want to ask you to take part in a study about one of the tablets (terizidone or 
PAS) that you are taking as part of your TB treatment. In the study we measure 
the amount of this tablet that goes into your blood and in this way we can see 
whether we are giving too much, too little or just enough of this specific medicine. 
To do this, we have to draw a small amount of blood from you. We will apply 
some ointment to your arm so that the needle prick will be less painful.  
A few minutes later we will use a needle to put a soft plastic tube in your arm. 
The needle will then be taken out and the plastic tube will stay in.  
From this plastic tube we will then take small amounts of blood 5 times in a few 
hours. We only have to prick you once in this time because we can take blood 
from the soft tube without pricking you again. We will then measure the amount 
of the medicine in your blood. The soft plastic tube will be taken out. The next 
morning we will take one more little bit of blood.  
You can decide if you want to be part the study or not. You do not have to take 
part if you don’t want to. You can decide at any time to stop being a part of the 
study if you are unhappy. 
 
Assent of minor 
I (Name of Child/Minor)……………………………………………. have been invited 
to take part in the above research project.  
 
• The study doctor/nurse and my parents have explained the details of the 
study to me and I understand what they have said to me. 
• They have also explained that this study will involve.  
• I also know that I am free to withdraw from the study at any time if I am 
unhappy. 
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• By writing my name below, I voluntary agree to take part in this research 
project.  I confirm that I have not been forced either by my parents or 
doctor to take part. 
 
 
............................................................... ....................................... 
Name of child Independent witness 
(To be written by the child if possible) 
Stellenbosch University  http://scholar.sun.ac.za/
 141 
 
PARTICIPANT INFORMATION AND INFORMED CONSENT FORM FOR 
RESEARCH INVOLVING GENETIC STUDIES 
TITLE OF RESEARCH PROJECT: “Pharmacokinetics and dosing rationale of 
terizidone and para-aminosalicyclic acid (PAS) in children and in-vitro 
metabolism of ethionamide, terizidone and PAS.” 
 
REFERENCE NUMBER: N09/08/212 
 
PRINCIPAL INVESTIGATOR:  Prof Bernd Rosenkranz 
 
ADDRESS: Department of Pharmacology 
          7th Floor, Clinical Building 
          Stellenbosch University 
          Tygerberg Campus 
          7505 
CONTACT NUMBER: 021 938 9331/ 0829550017 
We would like to invite your child to participate in a research study that involves 
genetic analysis and possible long-term storage of blood or tissue specimens.  
Please take some time to read the information presented here which will explain 
the details of this project.  Please ask the study staff or doctor any questions 
about any part of this project that you do not fully understand.  It is very important 
that you are fully satisfied that you clearly understand what this research entails 
and how your child could be involved.  Also, your participation is entirely 
voluntary and you are free to decline to participate.  If you say no, this will not 
affect your child negatively in any way whatsoever.  You are also free to withdraw 
your child from the study at any point, even if you do agree to take part initially.  
 
Stellenbosch University  http://scholar.sun.ac.za/
 142 
 
If you do not wish your child to participate in this genetic analysis part of the 
study, they can still be part of the main study of antituberculosis drug levels in the 
blood. The genetic analysis will then not be performed on your child’s blood. 
 
This research study has been approved by the ethics Committee for Human 
Research at Stellenbosch University and it will be conducted according to 
international and locally accepted ethical guidelines for research, namely the 
Declaration of Helsinki, and the SA Department of Health’s 2004 Guidelines: 
Ethics in Health Research: Principles, Structures and Processes. 
 
What is Genetic research? 
Genetic material, also called DNA or RNA, is usually obtained from a small blood 
sample.   Genes are found in every cell in the human body.  Our genes 
determine what we look like and sometimes what kind of diseases we may be 
susceptible to.  Worldwide, researchers in the field of genetics are continuously 
discovering new information that may be of great benefit to future generations 
and also that may benefit people today, who suffer from particular diseases or 
conditions. 
What does this particular research study involve? 
In the main part of the study in which your child is involved, the amount of 
antituberculosis drug in the blood will be measured at various time points. A 
number of factors can affect the amount of drug in a patient’s blood.  One of 
these is the ability of the liver to produce enzymes (substances which speed up 
chemical reactions).  These enzymes are responsible for the metabolism 
(breakdown) of drugs which are then passed out of the body.  
Some people produce more powerful enzymes than others and they are 
therefore able to break down drugs more quickly than other people.  This is 
because different people have differences in the genes which control how these 
enzymes are made. These variations in the genetic material of individuals are 
known as polymorphisms.  
This could possibly help us in the future to predict which children are likely to 
develop very high (which may be dangerous) or very low (the drug doesn’t work) 
concentrations, based on their genetic makeup. If we know their genetic makeup, 
we could perhaps take precautions or use a lower or higher dose of these drugs.  
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Why has your child been invited to participate? 
 
  Your child has been invited to participate because you have shown 
interest in the main part of our study and so we are going to measure 
blood concentrations of antituberculous drugs in your child. Performing 
genetic testing on your child will therefore help us determine if genetic 
differences (polymorphisms) can lead to high or low blood concentrations 
as explained above. 
 
What procedures will be involved in this research? 
Your child will not be required to give any additional blood or participate in 
additional procedures. The blood obtained from the main study will be used to 
perform genetic testing. 
 
Are there any risks involved in genetic research? 
In this study, we will be focusing on those genes which are responsible for the 
production of enzymes which break down or metabolize the drugs your child is 
receiving or drugs which broken down by the same kind of enzymes.  
This study therefore will not identify any diseases your child may develop or 
genetic problems which may lead to diseases later in life. 
Are there any benefits to your taking part in this study and will you get told 
your results? 
Your child will not benefit directly from taking part in this genetic research study. 
You will not be informed of the results. Blood will be stored and only tested at a 
later date once more is known about the enzymes responsible for drug 
breakdown and the genetic polymorphisms possibly involved.  
It is possible that in the future we can use the study results to predict which 
children are likely to develop very high (which may be dangerous) or very low 
(the drug doesn’t work) concentrations. If we know their genetic composition, we 
could perhaps take precautions or use a lower or higher dose of these drugs.  
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How long will your blood be stored and where will it be stored? 
The blood will be stored in the Division of Clinical Pharmacology and analyzed by 
the University of Stellenbosch. 
If your blood is to be stored is there a chance that it will be used for other 
research? 
Your blood will only be used for genetic research that is directly related to the 
metabolism of anti-TB drugs.  Also if the researchers wish to use your stored 
blood for additional research in this field they will be required to apply for 
permission to do so from the Human Research Ethics Committee at Stellenbosch 
University. 
If you do not wish your blood specimen to be stored after this research study is 
completed you will have an opportunity to request that it be discarded when you 
sign the consent form. 
How will your confidentiality be protected? 
The blood for DNA analysis will be labelled with your child’s participant number 
and not name, prior to storage. It will be labelled because we wish to compare 
your child’s blood concentration to their genetic results and so these must be 
linked by a participant number. 
All study records and samples will be kept confidentially in a sealed and locked 
area only accessible to the investigators. No one other than the investigators or 
the ethics committee of Stellenbosch University will have access to your child’s 
personal information. In the publication of results, your child’s name or identifying 
information will not be used 
Will you or the researchers benefit financially from this research? 
You will not be paid to take part in this study. 
Important information: In the unlikely event that this research leads to the 
development of a commercial application or patent, you or your family will 
not receive any profits or royalties 
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Declaration by participant 
 
By signing below, I …………………………………..…………. agree to take part in 
a genetic research study. 
I declare that: 
• I have read or had read to me this information and consent form and it 
is written in a language with which I am fluent and comfortable. 
• I have had a chance to ask questions and all my questions have been 
adequately answered. 
• I understand that taking part in this study is voluntary and I have not 
been pressurised to take part. 
• I have received a signed duplicate copy of this consent form for my 
records. 
 
Tick the option you choose: 
 
 I agree that my blood or tissue sample can be stored indefinitely/ 
stored for,………years, but I can choose to request at any time that 
my stored sample be destroyed. My sample will be identified with a 
special study code that will remain linked to my name and contact 
details. I have the right to receive confirmation that my request has 
been carried out.  (NB This option can be excluded completely if the 
genetic research has no clinical relevance to the patient and you plan 
to completely and permanently anonymise all samples) 
 
OR 
 Please destroy my blood sample as soon as the current research 
project has been completed.   
 
Signed at (place) ...............................................  on (date) ……………………. 
 
............................................................... .............................................. 
Signature of participant Signature of witness 
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Declaration by investigator 
I (name) ………………………………………………… declare that: 
• I explained the information in this document to 
…………………..……………... 
• I encouraged him/her to ask questions and took adequate time to 
answer them. 
• I am satisfied that he/she adequately understands all aspects of the 
research as discussed above. 
• I did/did not use an interpreter.  (If an interpreter is used then the 
interpreter must sign the declaration below. 
 
Signed at (place) ......................…........…………….. on (date) …………....……….. 
2005. 
............................................................... ................................................ 
Signature of investigator Signature of witness 
Declaration by Interpreter 
I (name) ………………………………………………… declare that: 
 
• I assisted the investigator (name) …………………………. to explain 
the information in this document to (name of participant) 
…………………………….. using the language medium of 
Afrikaans/Xhosa. 
• We encouraged him/her to ask questions and took adequate time to 
answer them. 
• I conveyed a factually correct version of what was related to me. 
• I am satisfied that the participant fully understands the content of this 
informed consent document and has had all his/her question 
satisfactorily answered. 
 
Signed at (place) ......................…........…………….. on (date) …………....……….. 
2005. 
............................................................... ............................................... 
Signature of interpreter Signature of witness 
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PARTICIPANT INFORMATION AND INFORMED CONSENT FORM FOR 
RESEARCH  
 
Title of research project: Pharmacokinetics and dosing rationale of terizidone 
and para-aminosalicylic acid (PAS) in children and the evaluation of the in vitro 
metabolism of ethionamide, terizidone and PAS. 
 
Principal Investigator:  Prof Bernd Rosenkranz 
Address: Faculty of Health Sciences, Stellenbosch University, Francie van Zijl 
Drive, Tygerberg, 7505 
Contact Numbers: Tel +27-21-938 9331 (Office); Cellular phone: +27-82-
9550017 
 
You are invited to take part in a research project.  Please take some time to read 
the information presented here, which will explain the details of this project.  
Please ask the study staff or doctor any questions about any part of this project 
that you do not fully understand.  It is very important that you are fully satisfied 
that you clearly understand what this research entails and how your child could 
be involved.  Also, your participation is entirely voluntary and you are free to 
decline to participate.  If you say no, this will not affect you negatively in any way 
whatsoever.  You are also free to withdraw from the study at any point, even if 
you do initially agree to take part. 
This study has been approved by the Committee for Human Research at 
Stellenbosch University and will be conducted according to the ethical 
guidelines and principles of the international Declaration of Helsinki, South 
African Guidelines for Good Clinical Practice and the Medical Research Council 
(MRC) Ethical Guidelines for Research. 
Introduction 
Tuberculosis (TB) is a very important health problem in South Africa and is often 
complicated by disseminated forms of TB such as meningitis or widespread 
lesions (miliary) TB, and resistance to the commonly used medicines. PAS, a 
second-line medicine is mostly used in combination with the commonly used 
drugs for the treatment of extensively resistant TB. When resistance is present 
other medicines (second-line medicines) must be used. These are not as 
effective as the medicines usually given for TB and they have more 
complications than the commonly used (first-line) medicines.  The medicines 
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used to treat extensively resistant TB almost always include PAS. The second-
line drugs such as PAS are not as effective as first-line TB drugs and it is 
therefore important that PAS be given in the best possible dosage. There is only 
very little information available regarding the amount of PAS that gets into the 
blood. Such information would make it possible for doctors to give much more 
accurate dosages of PAS than is possible at present.  This study aims to 
determine the amount of PAS that gets into the blood of TB patients following the 
currently recommended and used dose of PAS.   
Before you decide if you want to be a part of this study, we want you to know 
about the study. You may choose not to be part of this study. No health care will 
be withheld for you should you choose not to be part of the study. You will still 
receive the standard treatment for drug-resistant tuberculosis at this hospital.  
This is a consent form. It gives you information about this study.  The study staff 
will talk with you about this information.  You are free to ask questions about this 
study at any time.  If you agree to take part in this study, you will be asked to sign 
this consent form. You will get a copy to keep. 
Why is this study being done? 
The purpose of this study is to evaluate the absorption of the antituberculosis 
medicine PAS when given in the currently recommended dose in patients with 
drug-resistant TB.  
What will happen to me and what will I have to do if I participate in this 
study? 
If you decide to take part in this study, a number of investigations will be done. 
The absorption of the medicines will be studied by placing a needle in a vein and 
taking a small amount of blood 10 times soon after the medicines have been 
given. The amount of the medicine in the blood will then be measured. All of the 
above investigations will mean taking the volume of about 2 teaspoons of blood 
from you at two occasions approximately a month apart. 
How many patients will take part in the study? 
Up to 40 patients will be enrolled in the study. 
How long will you be in the study? 
The investigations will be completed as soon after being admitted to Brooklyn 
Chest Hospital as possible and the examination by the doctor and the blood 
investigations should be completed within a day and will be repeated about a 
month later.  
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Why might the doctor not admit me to this study? 
The study doctor may decide that you are too sick to take part in the study.  The 
study might also be cancelled by the site’s Ethics Committee (the committee that 
watches over the safety and rights of research subjects). 
What are the risks of the study? 
Your participation in this study will not increase the risk that you might be 
affected by PAS, but will increase the chance that such reactions will be detected 
early. A small amount of bleeding may occur at the site where the blood is taken 
from and this may leave a bruise which should soon heal. 
Are there benefits to taking part in this study? 
It is likely that you may derive no benefit from being in this study. Information 
from this study may, however, will help experts decide what dosage of PAS 
should be recommended for use.  
What other choices do I have besides this study? 
Should you decide that you do not want to take part in this study your treatment 
will be unaffected and will continue as usual.  Please talk to your doctor about the 
study if you should be uncertain as to whether you should take part in the study.   
What about confidentiality? 
Every effort will be made to keep your personal information confidential, however 
we cannot guarantee absolute confidentiality. Your personal information may be 
disclosed if required by law. On our study record we will use codes instead of 
your name. Only the study staff will know these codes. The study workers will not 
give out any information about you without written consent from you. Your 
family’s privacy will be respected. The public health authorities will be notified as 
usual if you have TB. Any publication of this study will not use your name or 
identify you personally. 
Your study records may be inspected by the South African Department of Health, 
study staff or study monitors. The study records will be kept separate from the 
normal medical records. 
What are the costs to me? 
There is no cost to you resulting from participation in the study. All medical care 
will be provided by the study doctor. 
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Will I receive any payment? 
We will re-imburse your transportation money to enable you to attend the hospital 
on the day that the study. 
What happens if I get injured? 
If you get injured injured as a result of being in this study, you will be given 
immediate treatment for your injuries at no cost to you. 
What are my rights as a research subject? 
Participation in this study is completely voluntary. You may choose not to take 
part in this study or withdraw from the study at any time. You will be treated the 
same no matter what you decide, there will be no penalty. 
We will tell you about new information from this or other studies that may affect 
your health, welfare or willingness to stay in this study.  If you want the results of 
the study inform the study staff. 
What do I do if I have questions or problems? 
For questions about this study or a research-related injury, contact either Prof 
Bernd Rosenkranz at the above address or the person who gave you this form.  
 
You can contact the Committee for Human Research at 021-938 9207 if you 
have any concerns or complaints that have not been adequately addressed by 
your child’s study doctor. 
You will receive a copy of this information and consent form for your own 
records. 
 
Declaration by patient 
 
By signing below, I ……………………………...……. agree to take part in a 
research study entitled: Pharmacokinetics and dosing rationale of terizidone 
and para-aminosalicylic acid (PAS) in children and the evaluation of the in 
vitro metabolism of ethionamide, terizidone and PAS. 
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I declare that: 
 
• I have read or had read to me this information and consent form and that it 
is written in a language with which I am fluent and comfortable. 
• I have had a chance to ask questions and all my questions have been 
adequately answered. 
• I understand that taking part in this study is voluntary and I have not been 
pressurised to take part. 
• I may choose to withdraw from the study at any time and will not be 
penalised or prejudiced in any way. 
• I may be asked to leave the study before it has finished if the study doctor 
or researcher feels it is in my best interests, or if I do not follow the study 
plan as agreed to. 
 
Signed at (place) .............…........…………….. On (date) …………....………..  
 
 
............................................................... ..................................... 
Signature of parent/legal guardian Signature of witness 
 
Declaration by investigator 
 
I (name) ……………………………………………..……… declare that: 
 
• I explained the information in this document to 
………………………………….. 
• I encouraged him/her to ask questions and took adequate time to answer 
them. 
• I am satisfied that he/she adequately understand all aspects of the 
research, as discussed above 
• I did/did not use an interpreter (if an interpreter is used, then the 
interpreter must sign the declaration below). 
 
Signed at (place) ..............…........…………….. On (date) …………....………..  
 
 
............................................................... ......................................... 
Signature of investigator Signature of witness 
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Declaration by interpreter 
 
I (name) ……………………………………………..……… declare that: 
 
• I assisted the investigator (name) ………….…………………………. to 
explain the information in this document to (name of parent/legal 
guardian) ……...………………………... using the language medium of 
Afrikaans/Xhosa. 
• We encouraged him/her to ask questions and took adequate time to 
answer them. 
• I conveyed a factually correct version of what was related to me. 
• I am satisfied that the parent/legal guardian fully understands the content 
of this informed consent document and has had all his/her questions 
satisfactorily answered. 
 
 
Signed at (place) ......................…........…………….. On (date) 
…………....………..  
 
 
 
............................................................... ............................................ 
Signature of interpreter Signature of witness 
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PARTICIPANT INFORMATION AND INFORMED CONSENT FORM FOR 
RESEARCH INVOLVING GENETIC STUDIES 
 
 
TITLE OF RESEARCH PROJECT: Pharmacokinetics and dosing rationale of 
terizidone and para-aminosalicylic acid (PAS) in children and the evaluation of 
the in vitro metabolism of ethionamide, terizidone and PAS. 
 
PRINCIPAL INVESTIGATOR: Prof Bernd Rosenkranz 
 
ADDRESS: Faculty of Health Sciences, Stellenbosch University, Francie 
van Zijl Drive, Tygerberg, 7505 
CONTACT NUMBER: Tel +27-21-938 9331 (Office); Cellular phone: +27-82-
9550017 
 
We would like to invite you to participate in a research study that involves genetic 
analysis and possible long-term storage of blood or tissue specimens.  Please 
take some time to read the information presented here which will explain the 
details of this project.  Please ask the study staff or doctor any questions about 
any part of this project that you do not fully understand.  It is very important that 
you are fully satisfied that you clearly understand what this research entails and 
how your child could be involved.  Also, your participation is entirely voluntary 
and you are free to decline to participate.  If you say no, this will not affect your 
child negatively in any way whatsoever.  You are also free to withdraw your child 
from the study at any point, even if you do agree to take part initially.  
 
If you do not wish to participate in this genetic analysis part of the study, they can 
still be part of the main study of antituberculosis drug levels in the blood. The 
genetic analysis will then not be performed on your blood. 
 
This research study has been approved by the ethics Committee for Human 
Research at Stellenbosch University and it will be conducted according to 
international and locally accepted ethical guidelines for research, namely the 
Declaration of Helsinki, and the SA Department of Health’s 2004 Guidelines: 
Ethics in Health Research: Principles, Structures and Processes. 
 
What is Genetic research? 
Genetic material, also called DNA or RNA, is usually obtained from a small blood 
sample.   Genes are found in every cell in the human body.  Our genes 
determine what we look like and sometimes what kind of diseases we may be 
susceptible to.  Worldwide, researchers in the field of genetics are continuously 
discovering new information that may be of great benefit to future generations 
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and also that may benefit people today, who suffer from particular diseases or 
conditions. 
 
What does this particular research study involve? 
 
In the main part of the study the amount of antituberculosis drug in the blood will 
be measured at various time points. A number of factors can affect the amount of 
drug in a patient’s blood.  One of these is the ability of the liver to produce 
enzymes (substances which speed up chemical reactions).  These enzymes are 
responsible for the metabolism (breakdown) of drugs which are then passed out 
of the body.  
 
Some people produce more powerful enzymes than others and they are 
therefore able to break down drugs more quickly than other people.  This is 
because different people have differences in the genes which control how these 
enzymes are made. These variations in the genetic material of individuals are 
known as polymorphisms  
  
This could possibly help us in the future to predict which patients are likely to 
develop very high (which may be dangerous) or very low (the drug doesn’t work) 
concentrations, based on their genetic makeup. If we know your genetic makeup, 
we could perhaps take precautions or use a lower or higher dose of these drugs.  
 
Why have I been invited to participate? 
 
You have been invited to participate because you have shown interest in the 
main part of our study and so we are going to measure blood concentrations of 
antituberculous drugs in you. Performing genetic testing on will therefore help us 
determine if genetic differences (polymorphisms) can lead to high or low blood 
concentrations as explained above. 
 
What procedures will be involved in this research? 
 
You will not be required to give any additional blood or participate in additional 
procedures. The blood obtained from the main study will be used to perform 
genetic testing. 
 
Are there any risks involved in genetic research? 
 
In this study, we will be focusing on those genes which are responsible for the 
production of enzymes which break down or metabolize the drugs your child is 
receiving or drugs which broken down by the same kind of enzymes.  
 
This study therefore will not identify any diseases or genetic problems which may 
lead to diseases later in life. 
 
Stellenbosch University  http://scholar.sun.ac.za/
 155 
 
 
 
Are there any benefits to your taking part in this study and will you get told 
your results? 
 
You will not benefit directly from taking part in this genetic research study. You 
will not be informed of the results. Blood will be stored and only tested at a later 
date once more is known about the enzymes responsible for drug breakdown 
and the genetic polymorphisms possibly involved.  
 
It is possible that in the future we can use the study results to predict which 
patients are likely to develop very high (which may be dangerous) or very low 
(the drug doesn’t work) concentrations. If we know your genetic composition, we 
could perhaps take precautions or use a lower or higher dose of these drugs.  
 
 
How long will your blood be stored and where will it be stored? 
 
The blood will be stored in the Division of Clinical Pharmacology and analysed by 
the University of Stellenbosch. 
 
If your blood is to be stored is there a chance that it will be used for other 
research? 
 
Your blood will only be used for genetic research that is directly related to 
the metabolism of antituberculosis drug PAS. If you do not wish your blood 
specimen to be stored after this research study is completed you will have an 
opportunity to request that it be discarded when you sign the consent form. 
 
 
How will your confidentiality be protected? 
 
The blood for DNA analysis will be labelled with your participation number and 
not name, prior to storage. It will be labelled because we wish to compare your 
child’s blood concentration to their genetic results and so these must be linked by 
a participant number. 
 
All study records and samples will be kept confidentially in a sealed and locked 
area only accessible to the investigators. No one other than the investigators or 
the ethics committee of Stellenbosch University will have access to your child’s 
personal information. In the publication of results, your child’s name or identifying 
information will not be used 
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Will you or the researchers benefit financially from this research? 
 
You will not be paid to take part in this study. 
 
Important information: In the unlikely event that this research leads to the 
development of a commercial application or patent, you or your family will 
not receive any profits or royalties. 
 
 
Declaration by participant 
 
By signing below, I …………………………………..…………. agree to take part in 
a genetic research study entitled (insert title of study). 
 
I declare that: 
 
• I have read or had read to me this information and consent form and it 
is written in a language with which I am fluent and comfortable. 
• I have had a chance to ask questions and all my questions have been 
adequately answered. 
• I understand that taking part in this study is voluntary and I have not 
been pressurised to take part. 
• I have received a signed duplicate copy of this consent form for my 
records. 
 
Tick the option you choose: 
 
 I agree that my blood sample can be stored indefinitely/ stored for     
………years, but I can choose to request at any time that my stored 
sample be destroyed. My sample will be identified with a special study 
code that will remain linked to my name and contact details. I have the 
right to receive confirmation that my request has been carried out 
OR 
 Please destroy my blood sample as soon as the current research 
project has been completed.   
 
Signed at (place) ...............................................  on (date) .............................. 
 
 
............................................................... ............................................. 
 
Signature of participant Signature of witness 
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Declaration by investigator 
 
I (name) ………………………………………………… declare that: 
 
• I explained the information in this document to 
…………………..……………... 
• I encouraged him/her to ask questions and took adequate time to 
answer them. 
• I am satisfied that he/she adequately understands all aspects of the 
research as discussed above. 
• I did/did not use an interpreter.  (If an interpreter is used then the 
interpreter must sign the declaration below. 
 
 
Signed at (place) ........................…………….. on (date) …………...20................... 
 
 
............................................................... ................................................ 
Signature of investigator Signature of witness 
 
Declaration by Interpreter 
 
I (name) ………………………………………………… declare that: 
 
• I assisted the investigator (name) …………………………. to explain 
the information in this document to (name of participant) 
…………………………….. using the language medium of 
Afrikaans/Xhosa. 
• We encouraged him/her to ask questions and took adequate time to 
answer them. 
• I conveyed a factually correct version of what was related to me. 
• I am satisfied that the participant fully understands the content of this 
informed consent document and has had all his/her question 
satisfactorily answered. 
 
Signed at (place) ............…........…………….. On (date) ……........ 20................... 
 
............................................................... ............................................... 
Signature of interpreter                                     Signature of a witness 
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Case record form 
Title of the project: Pharmacokinetics and dosing rationale of terizidone and 
para-aminosalicylic acid (PAS) in children and the evaluation of the in vitro 
metabolism of ethionamide, terizidone and PAS. 
Project No…………………………… 
Date………………………………….. 
Patient name………………………………………………… 
Date of birth………………………. 
Sex…………….. 
Race………………………………. 
Diagnosis…………………………………………………………………………… 
Measurements: 
Height (cm)…………………. 
Weight (kg)………………….. 
Mid upper arm circumference (cm)…………….. 
Drug for measurement (name)………………………………….Dose 
(mg)……………. 
Dosage time……………… 
Sampling time (min) Sample 
Planned Actual 
sampling 
Time 
(received) 
Remarks 
1 
 
    
2 
 
    
3 
 
    
4     
5     
6     
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Details of the co-administered drugs 
Drug (name) Dose(mg) Dosage time Duration of Rx 
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